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Abstract 
Sepsis, a systemic inflammatory response to an infection, is a significant cause of 
morbidity and mortality worldwide.  The microcirculation during sepsis fails, in part, due 
to microthrombosis and the resulting plugging of capillaries, precipitating organ failure.  
Intravenous injection of ascorbate has been shown to reduce capillary plugging, however 
the mechanism of this protective effect is unclear.  We hypothesized that ascorbate-
mediated destabilization of the microthrombi through promoting fibrinolysis could 
contribute to this protection. 
 We showed that streptokinase, a pro-fibrinolytic agent, reduced the capillary 
plugging to a similar degree as ascorbate.  This similarity provided the impetus for 
studying the effect of ascorbate on fibrinolysis.  Sepsis increased the urokinase 
plasminogen activator (u-PA) and tissue plasminogen activator (t-PA) mRNA expression 
in the skeletal muscle and liver in mice.  No effect of ascorbate was observed on u-PA or 
t-PA expression levels.  Sepsis also increased the plasminogen activator inhibitor 1 (PAI-
1) mRNA and protein expression and activity in these tissues, but ascorbate did not affect 
these increases. 
The local PAI-1 release by both platelets and endothelial cells may play a critical role in 
microthrombus formation in capillaries.  We observed that PAI-1 released by isolated 
endothelial cells was not affected by ascorbate.  However, thrombin-induced PAI-1 
release from platelets was inhibited by ascorbate pH-dependently.  We have also 
discovered that the PAI-1 release from platelets was nitric oxide independent. 
It has been shown that PAI-1 has a protective role in sepsis, namely that PAI-1 knockout 
leads to increased bacterial content, increased neutrophil apoptosis and increased 
mortality.  Therefore, the lack of effect of ascorbate on PAI-1 in the tissue may maintain 
PAI-1’s beneficial role in sepsis.  Consistently, we observed that sepsis-induced increases 
in bacterial count, PAI-1 expression and myeloperoxidase content in various organs were 
not affected by ascorbate.  
ii 
Overall, the lack of effect of ascorbate indicates that the protection by ascorbate through 
reduced capillary plugging is not through a fibrinolytic mechanism.  Other mechanisms 
such as platelet-endothelial cell adhesion and changes in red blood cell deformability in 
the capillaries should be explored as possible mechanisms of protection by ascorbate. 
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Chapter 1  
 
INTRODUCTION 
This thesis examines the role of the fibrinolytic system on the reduction in capillary 
perfusion observed during sepsis.  To this end, this thesis focuses on the role of 
plasminogen activator inhibitor 1 (PAI-1), an anti-fibrinolytic factor, in reduced capillary 
perfusion during sepsis, and examines whether ascorbate (reduced vitamin C) restores 
capillary perfusion and alters immune response in a PAI-1 dependent manner.  This 
introduction presents background information on: i) sepsis, and its contribution to 
reduced capillary perfusion, ii) fibrinolysis, including the components of coagulation 
leading to fibrin formation, and iii) ascorbate, including its beneficial effects in septic 
patients and animals. 
 
1.1 SEPSIS 
 
1.1.1 Epidemiology and significance 
Sepsis is a major cause of mortality worldwide, directly responsible for 1.4% of all deaths 
(76) and implicated in between 6-10% of all deaths in Canada and the United States of 
America each year (4, 106).  Research on sepsis has not reduced the mortality rate, which 
was reported to have increased by 0.67% per year between 1995 and 2005 (106).  As 
survival from sepsis is dependent on the availability of intensive care unit services, the 
mortality rate is most likely higher in developing countries with limited medical facilities 
(91).  The mortality rate of septic patients in Canada, the United States of America and 
European countries is between 20 and 47% (3, 66, 164).     
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 Sepsis is defined as a systemic inflammatory response to an infection (163).  A 
variety of criteria are used to confirm diagnosis of sepsis, including several scoring 
systems that assess the severity of particular symptoms.  Sepsis is difficult to diagnose as 
there are a variety of symptoms that may be present in an individual patient.  To make a 
diagnosis of sepsis, a patient must have a suspected or confirmed infection along with 
several of the following signs and symptoms: fever/hypothermia, tachypnea/respiratory 
alkalosis, positive fluid balance/edema, general inflammatory reaction, altered white 
blood cell count, increased levels of biomarkers (C-reactive protein, IL-6, procalcitonin), 
arterial hypotension, tachycardia, increased cardiac output, low systemic vascular 
resistance, high venous saturation O2, altered skin perfusion, decreased urine output, 
hyperlactatemia (increased base deficit), signs of organ dysfunction, hypoxemia, 
coagulation abnormalities, altered mental status, hyperglycemia, thrombocytopenia, 
disseminated intravascular coagulation, altered liver function (hyperbilirubinemia), and 
intolerance to feeding (altered gastrointestinal motility) (58).  In general, increasing 
numbers of symptoms indicate more severe sepsis, and a higher mortality (164). 
 In 2011, the only drug approved solely to treat sepsis, Drotrecogin alfa, was 
withdrawn due to a lack of efficacy (126).  As a result, currently the only treatment 
option available to physicians is supportive in nature, focusing on maintaining blood 
pressure and respiration while eliminating the bacterial infection, in the hope that the 
inflammation will resolve on its own (49).  Aside from the aforementioned Drotrecogin 
alfa, treatments targeting the inflammation and coagulation have at times shown promise 
(1, 108, 149) but were deemed to be either not effective or inconclusive in the treatment 
of sepsis.  Their use is either not recommended or used on a case by case basis as an 
experimental treatment.  Our lack of knowledge of the mechanisms involved in the septic 
pathophysiology has limited the development of drugs and other treatment strategies. 
 
1.1.2 Pathophysiology of sepsis 
The inflammatory response during sepsis is perpetuated by the production of cytokines 
intended to protect the host from the invading pathogens.  Infections caused by gram-
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negative bacteria initiate sepsis through the lipopolysaccharide (LPS) present on the 
bacterial wall.  The LPS interacts with toll-like receptor 4 (TLR4), primarily located on 
leukocytes and a key component of the innate immune system (135).  The activation of 
TLR4 causes the induction of a signaling cascade ultimately resulting in the production 
of various pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), 
interleukin-1β (IL-1β) and interleukin-6 (IL-6), all of which are markedly increased in the 
plasma of septic patients (51).  In gram-positive bacterial infections, substances such as 
lipoteichoic acid are secreted instead of LPS, activating TLR2 with similar production of 
cytokines (150).  Both TLRs signal through activation of NFκB (123).  The LPS-induced 
cytokine storm perpetuates the response by activating other components of the immune 
system and further recruiting cells such as the neutrophils and macrophages to the site of 
infection.  In addition stimulation of endothelial cells and platelets occur.  LPS and/or 
cytokines increase the levels of pro-aggregation and adhesive proteins, reactive oxygen 
species (ROS) and nitric oxide (NO) (123, 135).  The changes brought about due to the 
activation of the immune system, endothelial cells and platelets lead to many 
pathophysiological alterations such as systemic hypotension, reduced capillary perfusion, 
decreased ability to use the oxygen present, reduced resistance in the systemic 
vasculature and reduced cell-to-cell signalling in the cells lining the vasculature (14, 32, 
58, 77, 161-163).  These alterations lead to increasing maldistributions of blood flow and 
oxygen supply in the capillary bed, causing tissue damage and possible progression to 
organ dysfunction and failure (58, 140). 
 
1.1.3 Reduced capillary perfusion 
As alluded to previously, a reduction in capillary perfusion in various tissues of 
experimental animals and humans is a hallmark of sepsis (9, 13, 137).  Reduced capillary 
perfusion, defined as an increase in the number of capillaries with stopped flow, is 
believed to contribute to organ dysfunction and failure due to the reduction in oxygen 
delivery to the tissue (52, 158).  Lower oxygen delivery to the tissues, due to reduced red 
blood cells traveling through capillary beds lead to local tissue hypoxia and 
mitochondrial dysfunction.  Despite the resolution of septic shock in most patients, 
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reduced capillary perfusion leading to organ failure was still linked to a third of total 
patient deaths (131), while mortality increased as capillary perfusion decreased (156).  
Recent studies suggest that the reduced capillary perfusion is due in part to platelet 
adhesion and aggregation, and an increase in fibrin in the plugged capillaries (137).  
However, when platelets were depleted, capillary perfusion did not fully recover (137), 
indicating that the mechanism of capillary plugging is not exclusively due to platelet 
adhesion and aggregation. 
 It is important to note that, in sepsis, reduced capillary perfusion is due to 
plugging in capillaries themselves rather than plugging in the supplying arterioles or 
draining venules.  It has been observed that blood flow stops in capillaries even when 
these arterioles and venules are perfused (137, 159).  The presence of a precapillary 
sphincter (i.e., smooth muscle cells surrounding the vessel immediately upstream of the 
capillary) in skeletal muscle is debated.  Studies have found no evidence of a precapillary 
sphincter (37) or that the sphincter is present but not innervated (45), therefore 
contraction of a precapillary sphincter as a normal physiological process cannot 
adequately explain the lack of perfusion in select capillaries of the hind limb skeletal 
muscle (this process cannot be excluded from some other skeletal muscle beds such as 
the cremaster muscle (8)).  The lack of an influence from a precapillary sphincter points 
to the presence of a pathological process controlling the reduction in capillary perfusion 
during sepsis. 
 There are several possible factors that may contribute to capillary plugging.  
Leukocytes are large enough that should they adhere to the capillary wall they would 
fully occlude the capillary vessel.  There is merit in this, as leukocyte adhesion has been 
reported to increase during sepsis or endotoxemia (73, 103).  The relative contribution of 
leukocyte adhesion in the reduction in skeletal muscle capillary perfusion is likely low as 
very few leukocytes are observed in the septic skeletal muscle, instead being focused in 
the liver and lungs (104, 144).  It is for this reason that it was concluded that leukocytes 
play little role in the capillary plugging in the septic rat skeletal muscle (125).  Previous 
work in our lab confirmed that capillary plugging in a septic mouse skeletal muscle is not 
greatly influenced by leukocytes (137, 186).  In addition to leukocytes, red blood cells 
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could potentially contribute to capillary plugging due to their decreased deformability 
during sepsis (9, 110).  The role of red blood cell deformability in capillary plugging has 
not been directly studied during sepsis.  As the major components in microthrombi, 
platelets and fibrin can be expected to play some role in capillary plugging during sepsis.  
Indeed, both increased platelet activation and fibrin formation have been observed in 
septic animals and humans (83, 137, 140).  The formation of microthrombi in the 
capillaries, mediated by platelet sticking to the endothelium and fibrin mesh formation, 
would likely lead to the occlusion of at least some capillaries, blocking the flow of blood 
through those particular capillaries.  Platelet adhesion has been implicated in capillary 
plugging (137, 138), however investigating the role fibrin and the mechanism of its 
breakdown play in capillary plugging will be the focus of the present thesis.   
 During sepsis, fibrin breakdown decreases with increasing severity (61).  This 
would serve to increase the fibrin content in microthrombi, and combined with platelet 
trapping in the capillary bed would increase the chance large enough microthrombi could 
form to fully occlude the capillary flow.  Evidence supporting this effect includes our 
observation that capillaries typically go through a phase of intermittent flow prior to total 
stoppage, suggesting that the dynamic process of building up and breaking down the 
microthrombus slowly shifts from equilibrium to a progressively more pro–thrombotic 
state, ultimately leading to a plugged capillary when microthrombus breakdown is 
insufficient to maintain flow through the capillary (140).  
 
1.1.4 Oxidant production in sepsis 
 The major endogenous ROS molecules are the free radicals superoxide, hydroxyl 
and peroxynitrite.  The effects of ROS are localized due to the inability of the radicals to 
cross the cell membrane.  Unlike the free radicals, hydrogen peroxide, a non-radical 
substance, can freely diffuse across the cell membrane, and therefore spread damage 
beyond the cell in which the ROS was intitally produced (127).  All forms of endogenous 
ROS are essential in cell signaling and the maintenance of the normal homeostatic state 
in the body, and must be present in small quantities.  Superoxide is converted by 
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superoxide dismutase, located throughout the body, into hydrogen peroxide.  The 
hydrogen peroxide is inactivated through further conversion into water through the 
actions of catalase and glutathione peroxidase (34).  Superoxide also readily reacts with 
NO and forms peroxynitrite (127).  Under pathological conditions of enhanced NO and 
superoxide production, peroxynitrite can have detrimental effects on the nearby cells 
through damage of proteins, lipids and DNA (54). 
 There are a number of systems that contribute to ROS, however the only enzymes 
whose primary purpose is to produce superoxide are the NADPH oxidases found, for 
example, in neutrophils, macrophages and endothelial cells (15, 127).  It has been 
demonstrated that LPS and various inflammatory cytokines stimulate NADPH oxidase, 
increasing ROS production and thus making an important contribution to the 
pathophysiological state in sepsis (87, 179, 184). 
 Septic patients are known to have both greatly increased levels of inflammatory 
cytokines and reduced levels of the antioxidant ascorbate (28, 46, 63).  Indeed, ROS has 
been shown to have numerous effects during sepsis including inducing the coagulation 
cascade (62), activating platelets (25, 120) and causing endothelial dysfunction (7).  The 
combination of increased ROS production due to inflammatory cytokine signaling and 
reduced ascorbate levels likely result in enhanced oxidative stress (27).  It has been 
demonstrated that removal of the NADPH oxidase subunit gp91phox lessened the sepsis 
induced reduction in capillary perfusion (159) and reduced platelet adhesion (137), while 
treatment of mice or rats with ascorbate prevented or reversed the observed capillary 
plugging (5, 159, 160).   
 
1.1.5 Nitric oxide during sepsis 
NO has several important functions in vivo, including acting as a vasodilator, as a 
signaling molecule to maintain vascular homeostasis, and as an important component of 
the immune response.  NO has been demonstrated to inhibit platelet activation and 
aggregation (56, 74) and leukocyte adhesion to the endothelium and platelets (55, 74), 
 
7 
suggesting that local sources of NO may inhibit clot formation at the capillary level.  The 
endogenous source of NO is the three nitric oxide synthases (NOS), endothelial NOS 
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS).  The production of NO is 
facilitated by the NOS enzymes, where L-arginine is converted to L-citrulline in a two 
step process involving NADPH, H+ and O2.  NO synthesis occurs only in the presence of 
the calcium dependent co-factor calmodulin, flavin adenine dinucleotide, flavin 
mononucleotide, heme and tetrahydrobiopterin (BH4) (57).  The co-factors facilitate the 
movement of electrons from NADPH to heme, however if any step in this process is 
interrupted (referred to as uncoupling), such as the consumption of one co-factor, 
superoxide can be produced and released (42).   
 During sepsis there is increased NO production evidenced by the rise in nitrite 
and nitrate levels in the blood plasma of both humans and animals (81, 146).  The major 
source of increased NO is the increase in expression of iNOS through signaling by LPS 
and inflammatory cytokines such as TNFα (2).  It has been demonstrated that the 
increased NO production causes hypotension through arteriolar hyporeactivity and 
inappropriate vasodilatation (122).  Though iNOS is likely the major source of NO 
production during sepsis, genetic knockout of this, or either of the other two NOS 
isoforms (eNOS, nNOS) failed to improve the capillary perfusion, suggesting that the 
capillary plugging is not related to the arteriolar hyporeactivity or vasodilation resulting 
from excess NO production (159).  In another study, the use of iNOS inhibitors did 
improve the arteriolar blood pressure (16), suggesting that hypotension is not responsible 
for the reduced capillary perfusion seen in sepsis.  Ascorbate treatment does reduce 
capillary plugging in septic mice independently of iNOS or nNOS (137).  Interestingly, 
the beneficial effect of ascorbate is eliminated in eNOS-/- mice, suggesting that ascorbate 
functions through an eNOS dependent pathway.  The eNOS isoform is found primarily in 
the endothelial cells, while other cells such as platelets, erythrocytes and smooth muscle 
cells also express it (20, 53, 152).  The primary role of the NO produced by eNOS is to 
maintain vascular homeostasis through the regulation of vascular tone  and preventing 
platelet aggregation, apoptosis  and smooth muscle cell proliferation (22, 43, 48, 154).  
During various disease states including sepsis, the supply of BH4 can become depleted, 
leading to the uncoupling of the NOS (42).  Due to the uncoupling, superoxide is 
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produced and released by the NOS enzymes, further contributing to the ROS in the 
vasculature.  Additional peroxynitrite production due to impaired eNOS function is 
believed to cause further damage, particularly in the capillaries, leading to capillary 
plugging through activation of coagulation (159). 
 
1.1.6 Bacteria and the immune response during sepsis 
Though not essential to the development of the inflammatory response, a bacterial 
infection is most often present in patients presenting with sepsis.  Other less common 
sources of infection are fungi, viruses and parasites.  There are a multitude of bacterial 
infections that can lead to sepsis, with the most common sites of infection being the 
lungs, abdominal cavity and urinary tract (49).  An infection of the abdominal cavity 
commonly results in peritonitis, an inflammation of the peritoneum lining the peritoneal 
cavity.  Peritonitis can be caused by a ruptured appendix, perforation in the digestive tract 
or bacteria otherwise entering the peritoneal cavity (100, 124).  Many bacteria are 
typically present in the digestive tract, including both gram-negative and gram-positive 
species.  It has been determined that stool samples from the cecum of mice contain 
approximately 40 different species of bacteria, with Escherichia coli, Enterococcus and 
Staphylococcus strains dominating the aerobic bacteria content (147, 171).  Peritonitis 
occurs as a result of the presence of some or all of these bacteria, with the anaerobic 
bacteria likely playing the greatest role due to the anaerobic nature of the peritoneum 
(124). 
 The immune response to a bacterial infection begins with the activation of pattern 
recognition receptors by pathogen-associated molecular patterns present on bacteria (and 
other pathogens) and damage-associated molecular patterns released in response to cell 
damage caused by pathogens (50, 58, 169, 174).  There are four main classes of pattern 
recognition receptors in animals: the TLRs, C-type lectin receptors (CLR), NOD-like 
receptors (NLR) and RIG-I-like receptors (RLR) (58, 169).  In addition, there are a 
number of secreted pattern recognition receptors, such as C-reactive protein and lectins 
that are present in the blood and bind to invading pathogens to alert immune cells of the 
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presence of these pathogens (114).  The pattern recognition receptors activate the innate 
immune system, leading to inflammation and activation of the complement system (174).  
Inflammation, caused in part by various cytokines, increases blood flow to the infected 
tissue, leading to increased temperature, swelling and recruitment of leukocytes in an 
effort to kill the pathogen.  Typically, the first leukocytes arriving to a site of bacterial 
infection are the neutrophils, which phagocytose the invading bacteria, killing them with 
a respiratory burst involving the NADPH oxidase production of superoxide along with 
proteins released through degranulation, such as myeloperoxidase (139, 173).  
Macrophages arrive at the site of infection at the same time as neutrophils and also play a 
role by removing dead or dying cells, phagocytosing bacteria missed by the neutrophils, 
and producing inflammatory cytokines (24, 60).  The complement system, a cascade of 
proteins circulating in the blood, is the other component of the innate immune system.  
The inactive precursor complement proteins are activated by several different pattern 
recognition receptors, including C-reactive protein and mannose-binding lectin (19, 47).  
The complement system works by attracting neutrophils and macrophages, along with 
increasing vascular permeability and opsonizing bacteria (coating the bacteria increases 
phagocytosis) to weaken and destroy them (19, 128).  
 In cases of bacterial sepsis, it is believed that the immune response begins 
normally, with neutrophil recruitment and complement activation.  For some reason that 
has yet to be determined, the inflammatory response becomes aberrant and spreads to the 
entire body (58, 174).  The increase in inflammation leads to the activation of the 
coagulation system, further production of ROS and a decrease in fibrinolysis (140) (see 
sections 1.2 and 1.3 for further discussion of coagulation and fibrinolysis).  The 
prolonged inflammatory state directly or indirectly leads to many of the detrimental 
effects commonly seen in sepsis, including fever, hypotension and organ dysfunction and 
failure.  Though the bacterial infection is the initial trigger, often the inflammatory 
response actually causes more damage than the infection itself.  It is for this reason that 
antibiotics alone are often insufficient to treat sepsis (112). 
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1.1.7 Models of sepsis 
There are a number of models that have been used previously to study sepsis in a variety 
of different species.  Most studies, largely due to cost, are conducted in mice, though rats, 
rabbits, pigs, sheep and non-human primates such as baboons have been used in a variety 
of septic models (40, 168).  The models have been developed to attempt to best mimic the 
pathology observed in septic patients.  Most septic models are based on one of two basic 
pathogenic mechanisms: endotoxemia using a variety of inflammatory cytokines, and 
bacterial introduction through three main routes: direct injection of bacterial colonies into 
a host, cecal ligation and puncture (CLP), where the intestinal wall is compromised 
resulting in peritonitis, and fecal injection into peritoneum (FIP), where peritonitis is 
caused by administration of feces directly into the peritoneum.   
 
1.2 COAGULATION 
 
1.2.1 Overview 
Coagulation is the development of clots from blood.  Under physiological conditions, 
coagulation is essential for the maintenance of vascular homeostasis.  Initiation of 
coagulation begins with platelet activation and adhesion (see section 1.2.4), followed by 
strengthening of the developing clot with fibrin (see section 1.2.2).  Clot development 
and breakdown (fibrinolysis, see section 1.3) is a dynamic process that is tightly 
regulated under normal physiological conditions (89).  Dysfunction in this regulation, 
whether through hypercoagulation (excessive coagulation) or hypocoagulation 
(insufficient coagulation) has been shown to result in various pathological disease states 
(89, 101, 140).   
 Coagulation is initiated through two separate pathways: the contact activation 
pathway and the tissue factor (TF) pathway, both ultimately leading to a common 
pathway.  The contact activation pathway, or intrinsic pathway, is activated when 
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exposed collagen comes in contact with factor XII activating it to factor XIIa and 
beginning a cascade of activation first of factor XI to XIa, then factor IX to IXa and 
activation of factor X to Xa.  Under normal conditions, the endothelial cells form a 
barrier between the blood and collagen.  In addition to the contact activation pathway, 
platelets are directly activated when exposed to collagen and begin to adhere to the 
exposed site.  The TF pathway, or extrinsic pathway (illustrated in Figure 1.1a), is 
activated when blood comes in contact with TF produced mainly by cells not normally in 
contact with the blood.  This activates factor VII to VIIa, which then directly activates 
factor X to Xa.  Activated factor Xa initiates the common pathway for both coagulation 
pathways, with the conversion of prothrombin into the active protein thrombin.  
Thrombin then converts fibrinogen into fibrin, leading to the formation of a fibrin mesh 
in the developing clot.  Thrombin also further activates platelets and endothelial cells (30) 
and causes a positive feedback activating factor VII to VIIa, therefore increasing the 
production of thrombin further (89).  Under physiological conditions, most TF is 
produced by vascular cells not in direct contact with the blood, however during 
pathological conditions, upon stimulation by inflammatory cytokines, endothelial cells 
and white blood cells have been shown to release TF (35).   
 It is common in septic patients to observe a wide variety of disorders in the 
coagulatory system, including disseminated intravascular coagulation (DIC, consumption 
of coagulation proteins in the microvasculature, ultimately resulting in consumption of 
coagulatory factors leading to an inability to form clots), while thrombocytopenia (a 
reduction in platelet count) can occur alone or in conjunction with DIC (84, 140).  It has 
been shown that there is extensive cross-talk between the inflammatory and coagulation 
proteins, with many inflammatory cytokines activating the coagulation system.  LPS 
itself has been shown to increase the production of TF (148), while cytokines such as 
TNFα have also been demonstrated to upregulate TF (11).  As LPS itself induces the 
production of TNFα, this would have a positive feedback in generating even more TF and 
enhancing thrombin production.  Inflammation has also been observed to alter 
coagulation through a reduction in the levels of anti-coagulation proteins protein C (an 
enzymatic inactivator of factors Va and VIIIa), tissue factor pathway inhibitor (an 
inhibitor of thrombin as well as factor Xa, and ultimately inhibits the factor VIIa-TF
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Figure 1.1.  Schematic of the coagulation (Panel A) and fibrinolytic (Panel B) 
pathways during sepsis.  Panel A:  The coagulation system is initiated in sepsis by the 
activation of TLR4 by LPS.  This generates ROS, TF and cytokines that begin the 
coagulation cascade.  Coagulation occurs when the platelets become activated and fibrin 
is formed, together composing the thrombus.  As ascorbate acts as an antioxidant (see 
section 1.4), I propose that ascorbate reduces the ROS and thereby inhibiting the 
activation of the coagulation cascade.  Panel B:  I propose that activation of TLR4 also 
initiates production of PAI-1, which then inhibits t-PA and u-PA (see section 1.3).  This 
leads to lower plasmin production and impaired fibrin degradation.  Upon ascorbate 
treatment, PAI-1 expression is reduced restoring plasmin production and fibrin 
degradation.  Activation of factors is indicated by arrows, inhibition is indicated by a T 
line and reduced production during sepsis is indicated by an X.  
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complex in conjunction with factor Xa), and antithrombin (an inhibitor of thrombin) (84, 
89).  In addition to enhancing coagulation, the breakdown of fibrin through the 
fibrinolytic pathway can also be inhibited by inflammation (see section 1.3) (140). 
1.2.2 Fibrin 
Fibrin is a fibrous protein formed from its precursor fibrinogen during the blood clotting 
process.  It forms a polymerized mesh giving the blood clot strength and stability.  
Besides the role in clot formation and support, fibrin is also involved in signal 
transduction, eliciting cellular responses critical to normal cellular function (44, 178).  
Fibrin is formed when thrombin cleaves the N-terminus of the fibrinogen α and β 
subunits.  This allows the cleaved ends to polymerize end to end with other fibrin 
molecules (170).  It is the cross-linking of fibrin molecules into a mesh that ensures the 
structural integrity and three dimensional nature of the clot (172).   
 During sepsis, fibrin content is markedly increased due to increased TF mediated 
thrombin generation (84, 89).  In addition, fibrin degradation (fibrinolysis, see section 
1.3) is reduced during sepsis (140), suggesting that both increased fibrin production and 
stability contribute to the pathological clot formation during sepsis.  
 
1.2.3 Endothelial cells 
The endothelial cells that line the blood vessel walls are essential for vascular function by 
forming a barrier between the surrounding cells and the vascular lumen as well as 
facilitating critical components of the coagulation and inflammatory processes.  
Endothelial cells produce and express several important adhesion proteins including P-
selectin and von Willebrand factor (vWF) as well as the anti-fibrinolytic factor PAI-1 
(96, 142).  Upon activation, the Weibel-Palade bodies that contain the P-selectin and 
vWF are expressed at the cell surface, facilitating the capture of platelets and coagulation 
proteins.  The secretion of PAI-1 by endothelial cells serves to stabilize the clots through 
its anti-fibrinolytic activity.  It has been demonstrated that endothelial cells can be 
activated by numerous molecules, proteins and cytokines including LPS, thrombin, and 
 
14 
TNFα (39, 59, 145).  Endothelial cells can be damaged during sepsis, resulting in a loss 
of the normal barrier function, allowing for increased vascular permeability and exposure 
of the basement membrane and surrounding cells to the vascular lumen (64).  The 
resulting loss of barrier function can result in activation of coagulation and edema (82). 
 
1.2.4 Platelets 
Platelets are small anucleated cells derived from the fragmentation of precursor 
megakaryocytes.  They are small in size, their diameter ranging between 1-3 microns.  
Platelets are essential to maintaining normal vascular homeostasis, primarily through a 
contribution to the formation of clots.  When activated, platelets aggregate and adhere to 
adhesion molecules expressed on other cells, forming and strengthening the clots.  In 
addition to clot formation, platelets also play an essential role in the repair and 
regeneration of connective tissues and other damaged tissues surrounding the vasculature 
(117).   Pathological disorders may result in altered platelet numbers or function.  Low 
platelet count (thrombocytopenia), or reduction in function (thrombasthenia), result in 
excessive bleeding, while high platelet count (thrombocytosis) leads to pathological 
clotting (141).   
 Activation of platelets occurs through exposure to a number of substances, 
including thrombin, vWF, collagen, adenosine diphosphate, and thromboxane A2 
produced by other platelets (88, 116).  Upon activation, platelets change shape becoming 
more spherical allowing for enhanced adhesion through increased platelet rolling (105).  
Activated platelets also secrete three types of granules: dense, lambda and alpha.  The 
dense granules release molecules essential for the coagulation response (116).  Alpha 
granules release the pro-coagulation proteins including P-selectin, vWF, fibrinogen, and 
the anti-fibrinolytic protein PAI-1 along with other proteins (88).  The molecules secreted 
from these granules serve as positive feedback to activate platelets as well as other 
components of the coagulation and anti-fibrinolytic pathways (88, 116).   
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 Thrombocytopenia is common in septic patients (10, 65), though the exact 
reasons for the reduction in platelet count remain unresolved.  It is known that activation 
of coagulation does occur during sepsis, including platelet activation.  The increased 
release of thrombin, adenosine diphosphate, and thromboxane A2 (along with other 
substances) during sepsis activates platelets leading to increased adhesion to the 
vasculature and increased platelet aggregation (23, 70, 75, 84, 85, 99, 134, 140).  In 
addition, LPS and inflammatory cytokines have been shown to activate platelets (26, 119, 
185), resulting in an increase in TF (130, 134).  ROS has also been demonstrated to 
increase platelet aggregation (21, 29, 166), while activated platelets have been shown to 
release ROS (132, 166). 
 
1.3 FIBRINOLYSIS 
 
1.3.1 Overview 
Fibrinolysis is the process by which fibrin is broken down, leading to the dissolution of 
blood clots.  Under normal physiological conditions, fibrinolysis removes clots that are 
no longer needed, as well as regulating the size of clots so they do not become too large.  
Fibrinolysis is initiated by the activation of plasmin from its precursor plasminogen (see 
Figure 1.1B).  Plasmin cleaves fibrin into degradation products, dissolving the fibrin 
mesh and allowing for the dispersal of the clot.  Abnormal fibrinolysis, either through 
inhibition or over activation, has been associated with pathological disease states (67, 
102).   
 Fibrinolysis is inhibited by two separate means, namely inhibiting plasmin 
production, and directly inhibiting plasmin.  Plasmin production is inhibited by the 
plasminogen activator inhibitors, while α2-antiplasmin is the primary molecule 
responsible for inactivating plasmin (67, 133).  A disease process targeting either 
pathway could alter fibrinolysis, either through the stabilizing effect of preserving fibrin, 
or the anti-coagulation effect of uncontrolled fibrin degradation (86, 93, 167). 
 
16 
1.3.2 Plasmin 
Plasmin becomes an active enzyme upon cleavage from the inactive zymogen 
plasminogen.  Plasminogen is produced in the liver, circulates in the blood and is 
incorporated into clots.  Two activators of plasminogen, tissue plasminogen activator (t-
PA) and urokinase plasminogen activator (u-PA), cleave the molecule into plasmin when 
plasminogen is bound to a clot or cell surface (90, 107).  Active plasmin cleaves fibrin 
and vWF along with several other pro-coagulation proteins into inactive degradation 
products, such as D-dimers in the case of fibrin (90, 143).  Both t-PA and u-PA are 
produced by a wide variety of cells, and interact with plasminogen, fibrin and in the case 
of u-PA, the u-PA receptor, to produce plasmin (90, 94).  Plasmin is permanently 
inactivated by α2-antiplasmin, halting the degradation of fibrin (80).  Diseases that cause 
pathological increases in the expression of t-PA or u-PA lead to hyperfibrinolysis and a 
lack of clot stability and longevity (36, 118), whereas decreases lead to unchecked 
clotting (33, 86).  Decreased α2-antiplasmin under various disease conditions results in 
an inability to maintain clots due to enhanced fibrinolysis.  Increased α2-antiplasmin has 
not been reported to occur (18, 71).   
During sepsis, both t-PA and u-PA have been reported to have increased 
expression, however this increase is likely counteracted by increases in the inhibitory 
plasminogen activator inhibitors (129).  Plasmin-antiplasmin complexes are increased 
during sepsis, supporting the notion that plasmin production is increased during sepsis, 
however increased plasmin may be offset by increased anti-fibrinolytic activity (86, 93, 
102, 157). 
 
1.3.3 Inhibition of plasmin 
The production of plasmin is regulated by a dynamic balance between the plasminogen 
activators (t-PA and u-PA) and their inhibitors PAI-1 and plasminogen activator inhibitor 
2 (PAI-2).  PAI-1 is the primary inhibitor of the activation of plasmin, acting through the 
irreversible inhibition of both t-PA and u-PA (31).  PAI-1 is produced by a variety of cell 
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types, however in regards to intravascular clotting, the primary source is endothelial cells 
(94).  Inhibition of t-PA and u-PA eliminates the activation of plasmin therefore 
stabilizing clots.  Active PAI-1, the only form of PAI-1 with a known biological action, is 
extremely unstable and spontaneously inactivates to a latent form unless stabilized by 
vitronectin (17).  The other known plasminogen activator inhibitor is PAI-2, however this 
inhibitor is not generally detectable in non-pregnant patients, and has been reported to be 
no more than five percent of the overall inhibitor content in the body (129).  Pathological 
changes in the production of PAI-1 have been reported, with depressed levels leading to 
reduced ability to clot, and increased PAI-1 results in an inability to break down fibrin, 
possibly leading to the formation of fibrosis, which can ultimately lead to organ damage 
if allowed to occur over the long term (68, 69, 98, 115).   
 PAI-1 has been demonstrated to be increased during sepsis, while some reports 
have observed an increase in PAI-2 as well (93, 95, 102, 129, 182).  Overall, this leads to 
an increase in anti-fibrinolysis, where less plasmin is produced.  It is unclear whether this 
increase just counteracts the observed increase in t-PA and u-PA or whether the increased 
PAI-1 creates an even greater anti-fibrinolytic state (86, 94).   
 In addition to its fibrinolytic effects, PAI-1 has been demonstrated to play a role 
in angiogenesis, macrophage migration and neutrophil efferocytosis (17, 79, 121).  It is 
interesting to note that all of these activities are related to wound healing and, as such, 
PAI-1 clearly plays an essential role in this process.  In addition, increasing evidence 
points to a role of PAI-1 in obesity and cancer, where aberrant expression promotes 
vascularization and therefore tumor growth (17). 
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1.4 ASCORBATE 
 
1.4.1 Overview 
Ascorbate (a reduced form of vitamin C) is a water soluble antioxidant available extra- 
and intra-cellularly in the body.  Its primary function is to react with ROS (superoxide, 
hydroxyl and peroxynitrite radicals), neutralizing the harm these radicals can cause.  
Upon reaction between ascorbate and a free radical, ascorbate loses its reactivity and can 
convert to dehydroascorbic acid (175).  Ascorbate also plays a critical role in the 
recycling of the antioxidant α-tocopherol (vitamin E) (155).   
In humans, ascorbate is an essential vitamin obtained from diet, as the ability to 
produce ascorbate has been lost.  In contrast, most rodents produce their own supply of 
ascorbate.  During sepsis, blood plasma levels of ascorbate are markedly reduced (e.g., 
from 60 to 10 µM) in both patients and animals regardless of the ability to produce 
ascorbate (5, 46).  Indeed, there has been a report of a critically ill patient developing 
scurvy (vitamin C deficiency) due to depletion of ascorbate in the blood plasma (63).  It 
is believed that impairment of the mechanisms of ascorbate recycling occurs during 
sepsis (12).  There is increased consumption of ascorbate in septic patients in order to 
neutralize the increased ROS levels (12, 92, 175-177).  Decreased plasma ascorbate 
levels have been linked with decreased survival and more severe illness in septic patients 
(46, 54, 177). 
 
1.4.2 Treatment with ascorbate 
Ascorbate, administered with vitamin E has been demonstrated to reduce organ failure, 
shorten recovery time, and improve survival in critically ill patients (28, 113).  Ascorbate 
has also been shown to reduce mortality in burn victims and restore depleted plasma 
levels in septic patients when given at high doses of greater than 1g per day (12, 92, 151).  
In addition, the antioxidant succinobucol has been shown to reduce TF expression in LPS 
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stimulated endotoxemia (97), thereby reducing coagulation and suggesting that sepsis 
derived ROS plays a role in the initiation of coagulation.   
Ascorbate given as an intravenous bolus has been demonstrated to enhance 
capillary perfusion and responsiveness in the arterioles, improve the function of the liver, 
reverse hypotension and decrease mortality in rodent models of sepsis (5, 137, 159, 160, 
180, 181).  Ascorbate reduced capillary plugging (137), and platelet activation and 
aggregation in septic models (138).  Capillary plugging has been demonstrated to 
improve with ascorbate treatment when given with the onset of sepsis (5), as well as six 
hours into sepsis, at a time when approximately 40% of capillaries were non-perfused 
(137, 159, 160).  The administration of ascorbate restored perfusion to approximately half 
of the previously non-perfused capillaries (137, 159, 160).  The improvement in capillary 
perfusion in mice with ascorbate treatment is consistent in both a cecal ligation and 
perforation (CLP) model (180) and a fecal injection into peritoneum (FIP) model (159). 
 
1.4.3 Effects of ascorbate 
As ascorbate acts as an antioxidant, it is likely that its protective effects would be at least 
partly due to its ability to scavenge ROS in septic patients.  Indeed, it has been 
determined that removal of the gp91phox subunit of NADPH oxidase, eliminating the 
NADPH oxidase ROS contribution, reduces capillary plugging, and that ascorbate 
improves capillary perfusion to a similar degree (137).  In addition, the protective effect 
of ascorbate is eNOS dependent, likely through eNOS derived NO production, as the 
addition of endogenous NO or tetrahydrobiopterin (BH4), an eNOS cofactor, both 
improved capillary perfusion (159).  The use of BH4 or ascorbate on eNOS-/- mice was 
ineffective in reversing the capillary plugging (137, 159).  As BH4 is oxidized by ROS, 
which then uncouples from eNOS, increased ROS during sepsis ultimately leads to the 
production of superoxide rather than NO, causing cellular damage through the production 
of peroxynitrite (41, 78, 136).  Ascorbate is known to be rapidly and readily taken up by 
endothelial cells (175, 176).  The antioxidant activity of ascorbate likely prevents the 
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oxidation of BH4, resulting in a state of normal coupling of eNOS and resulting in 
restored NO production (177).   
 NO prevents platelet activation and aggregation, and is one of the mechanisms 
whereby NO maintains normal vascular homeostasis.  One way NO prevents platelet 
activation is through a reduction in the expression of the adhesion protein P-selectin on 
both platelets and endothelial cells, though iNOS derived NO actually increases P-
selectin expression (6, 56, 183).  Reduced P-selectin decreases platelet-endothelial 
adhesion and thrombus size (38, 56, 153), while ascorbate has been shown to reduce P-
selectin expression (138).  It must be noted that as PAI-1 is co-localized in the α-granules 
in platelets, it is possible that a reduction of P-selectin expression may also indicate 
reduced PAI-1 release, increasing fibrinolysis at the capillary level (88).  Interestingly, 
ascorbate was able to reduce P-selectin surface expression on platelets in a NO 
independent manner (138), suggesting that α-granule secretion may be controlled by both 
NO and another mechanism unrelated to its antioxidant properties. 
 Recently, it has been determined that ascorbate reduces neutrophil extracellular 
trap formation, resulting in reduced cellular damage from excessive neutrophil activation 
(109).  There is ample evidence that ascorbate affects numerous aspects of the 
inflammatory and coagulation systems, however the potential protective effects on the 
fibrinolytic system remain to be determined. 
 
1.5 RATIONALE, HYPOTHESIS AND OBJECTIVES 
 
1.5.1 Rationale 
Extensive research on sepsis has been conducted, yet no effective pharmacological 
treatment targeting the inflammation has been developed.  The failure of several 
experimental treatments at the clinical trial stage reflects the lack of understanding of the 
pathophysiology of sepsis at the molecular and cellular level.  It has been demonstrated 
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that capillary perfusion is reduced during sepsis, with poorer prognosis with increasing 
microvascular dysfunction (5, 77, 131).  It has been demonstrated that increased platelet 
adhesion occurs in the skeletal muscle capillaries during sepsis, and that depletion of 
platelets improves the capillary perfusion (137).  In addition, studies have shown 
increased fibrin deposition and a decrease in fibrinolysis during sepsis (84, 140).  
However, complete removal of platelets, fibrin or the anti-fibrinolytic factor PAI-1 result 
in decreased capillary perfusion or markedly reduced survival (72, 111, 137).  The poor 
prognosis through removing these critical components of coagulation highlights the 
complexity of this process and our lack of understanding of the mechanisms involved.  
The presence of both platelets and fibrin in capillaries shows that the capillary plugging is 
caused by a physical blockage due to clot formation (137).  To date, the role fibrinolysis 
plays as it directly relates to capillary plugging has yet to be explored. 
 It has been many years since ascorbate treatment was shown to have beneficial 
effects during sepsis, with a link becoming apparent as early as 1990 (165).  In the years 
since, it has been determined that ascorbate improves the capillary plugging (5), survival 
(159), and most recently decreases platelet adhesion (137, 138).  Despite these studies, 
the mechanisms by which ascorbate facilitates these beneficial effects remains largely 
undetermined.  Ascorbate acts as an antioxidant, and its beneficial effects in reducing 
capillary plugging is eNOS dependent in vivo, likely through the NO produced by eNOS 
(137).  However, it must be noted that ascorbate also has an effect on platelet adhesion 
that is NO independent (138).  This discrepancy suggests at least two separate 
mechanisms play a role in the protective effect of ascorbate.  As platelet depletion does 
not restore capillary perfusion to the same extent as ascorbate (137), clearly ascorbate has 
an effect on other systems in sepsis.  As fibrin and adherent platelets were both located in 
the non-perfused septic microvasculature (137), removal of fibrin through increased 
fibrinolysis may enhance the capillary perfusion in conjunction with reduced platelet 
adhesion.  Exploration of the fibrinolytic state during sepsis will further elucidate the 
mechanism of ascorbates protective effect as well as support the use of ascorbate as an 
effective adjuvant therapy for sepsis. 
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1.5.2 Hypotheses 
1) Increased fibrinolysis results in reduced capillary plugging during sepsis. 
2) PAI-1 expression in a septic mouse model is increased, leading to decreased 
fibrinolysis. 
3) Ascorbate promotes fibrinolysis in the skeletal muscle through a decrease in PAI-1 
expression, restoring capillary perfusion during sepsis. 
 
1.5.3 Objectives 
1)  Determine the effect of increased fibrinolysis on capillary perfusion in sepsis, and test 
whether sepsis and ascorbate can alter the levels of pro- and anti-fibrinolytic factor 
mRNA and protein expressions in an in vivo model of sepsis.  This objective will be 
addressed in Chapters 2 and 3. 
2) Determine the effect of ascorbate on bacterial levels and the immune response in septic 
organs.  This objective will be addressed in Chapter 3. 
3)  Develop an ex vivo/in vitro model of sepsis to determine the effect of ascorbate on 
sepsis-induced PAI-1 expression and release from platelets and endothelial cells.  This 
objective will be addressed in Chapter 4. 
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Chapter 2  
 
Effect of ascorbate on fibrinolytic factors in septic mouse 
skeletal muscle 
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2.1 INTRODUCTION 
 
Sepsis, the systemic inflammatory response to a local infection, leads to reduced capillary 
bed perfusion and subsequent organ failure (33).  Reduced perfusion of the 
microvasculature in tissues correlates with organ failure and mortality during sepsis (24).  
Using intravital microscopy, we have demonstrated that this reduction in 
microcirculatory flow is due to a significant increase in the number of stopped-flow, or 
plugged, capillaries (25, 30). The sepsis-induced coagulation of the microcirculation 
involves platelet activation and adhesion, fibrin deposition, and both the formation and 
strengthening of micro-thrombi (11). Furthermore, the opposing process of fibrinolysis 
(breakdown of fibrin) is reduced in blood during sepsis (8). Subsequently, the micro-
thrombi within the microvasculature are an important contributor to the blood flow 
impairment in sepsis. The fibrinolytic process involves the pro-fibrinolytic t-PA and u-
PA, and the anti-fibrinolytic PAI-1, which inhibits t-PA and u-PA (29).  
We also demonstrated in a mouse model of sepsis that an intravenous injection of the 
antioxidant ascorbate at 6 h of sepsis (i.e., time when capillary plugging is prevalent) 
restores capillary blood flow at 7 - 18 h of sepsis (30). Since ascorbate does not affect 
arterial pressure post-injection (30), a local mechanism within the microvasculature could 
be responsible for the restoration of capillary blood flow. Numerous local mechanisms 
could explain this effect (4, 36), including the possibility that ascorbate enhances 
fibrinolysis in septic capillaries, and thus restores blood flow. To this end, oxidative 
stress has been shown to increase both mRNA and protein expression of t-PA, u-PA and 
PAI-1 in endothelial cells (20).   
To our knowledge, the effect of ascorbate on the fibrinolytic process in the septic 
microvasculature has not been examined. The objective of the present study was to 
determine the effect of sepsis and ascorbate on t-PA, u-PA and PAI-1 mRNA and protein 
levels in the mouse model of sepsis. We hypothesized here that ascorbate restores blood 
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flow in septic capillaries by stimulating local fibrinolysis via increasing t-PA and u-PA 
and/or by inhibiting PAI-1 levels within the septic microvasculature.  
 
2.2 METHODS 
 
2.2.1 Animal preparation 
All experimental protocols were approved by the University of Western Ontario Council 
on Animal Care. Male wild type C57BL/6 mice (weight: 18-25 g, age: 1.5-4 months) 
were obtained from the Jackson Laboratory (Bar Harbor, ME) and bred in our animal 
facility. Sepsis was induced by fecal injection into peritoneum (FIP) as detailed 
previously (25, 30). Briefly, feces was collected from the cecum of a minimum of two 
donor mice for each experiment, suspended in sterile saline at a concentration of 75 mg 
of feces/mL and stored overnight at 4°C. The following day, mice were anesthetized with 
ketamine (80 mg/kg) and xylazine (4 mg/kg) prior to being injected intraperitoneally with 
50 mL/kg of the feces solution. For our control sham mice, we substituted sterile saline 
for the feces solution. All mice were given a subcutaneous injection of 1 mL of sterile 
saline containing the analgesic buprenorphine (4 µg/mL) 30 minutes prior to FIP. 
At 5 - 6 h post-FIP, the mice were anesthetized with ketamine and xylazine and kept 
anesthetized with supplemental ketamine/xylazine doses for the remainder of the 
experiment (1.5 h). The extensor digitorum longus (EDL) muscle was surgically exposed 
and its surface was epi-illuminated and imaged using intravital microscopy as previously 
detailed by us (25, 30).  The EDL muscle was chosen because it is a suitable organ for 
intravital microscopic examination of blood flow in the capillary bed.  Other organs 
present difficulty with this examination due to the breathing movement of the animal and 
due to extensive surgery required to expose the capillary bed.  It has been demonstrated 
that the EDL capillary perfusion during sepsis shows the same fundamental features (e.g., 
blood flow stoppage during sepsis) as the liver, kidney, skin, sublingual surface, heart, 
lung and brain (1, 24).  We have used the EDL as a surrogate organ of the sepsis-induced 
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capillary derangement in the other organs.  Briefly, we used an upright microscope and 
video-recorded 5 random fields (0.61 x 0.87 mm) per muscle. In each field we drew a test 
line perpendicular to muscle fibers and counted capillaries perfused with red blood cells 
and capillaries with stationary red blood cells (i.e., stopped-flow capillaries) crossing this 
test line. We computed the percentage of stopped-flow capillaries from the total (perfused 
+ stopped) and averaged the percentages from 5 fields. We used the intravital recordings 
to verify that sepsis impaired capillary blood flow at 5 - 6 h post-FIP and to compute the 
percentage of stopped-flow capillaries at 7 h (25, 30). At 5 or 6 h, we injected an 
intravenous bolus (0.1 mL) of streptokinase (Sigma-Aldrich, Oakville, ON, 25000 U/kg), 
ascorbate (Sigma-Aldrich, 10 mg/kg) (both dissolved in sterile saline), or saline. The 
ascorbate dose is clinically relevant, as intravenous doses of the order of 1 g/day have 
been given to critically ill patients (12).  To examine the effect of ascorbate on 
fibrinolytic factors in skeletal muscle, we harvested this tissue at 7 h for mRNA and 
protein analyses of these factors.  We also harvested the liver at 7 h, because the liver 
could be a major source of fibrinolytic factors (22), which could be released into the 
bloodstream and thus indirectly affect the microcirculation in the skeletal muscle.  
Alternatively, we isolated microvascular endothelial cells from the skeletal muscle at 7 h 
by excising, mincing and digesting the muscle in a collagenase enzyme solution and by 
subjecting it to immunoseparation using lectin-coated magnetic beads as detailed 
previously (2, 15).   The purity of the endothelial cell isolates were not confirmed due to 
limited cell availability, however we previously confirmed this method yields high purity 
through vWF expression (2, 15).  To assess the plasma level of the fibrinolytic factors, 
we punctured the carotid artery to collect a systemic blood sample in sodium citrate.  
Finally, we also collected blood in heparin for platelet count and thrombelastography.  
 
2.2.2 mRNA expression 
To extract mRNA, we used Trizol (Invitrogen, Burlington, ON) according to the 
manufacturer’s directions. We treated the mRNA with DNAse I (Sigma-Aldrich) 
followed by reverse transcription using Superscript II reverse transcriptase (Invitrogen). 
We used qPCR to determine the mRNA expression levels of t-PA (primers: forward 5’-
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CTGAGGTCACAGTCCAAGCAATGT-3’ and reverse 5’-
GCTCACGAAGATGATGGTGTAAAGA-3’), u-PA (primers: forward 5’-
GCCGCTATCCTACAGAGCAC-3’ and reverse 5’-CAAGGGTATTGTTCCCCTCA-
3’) and PAI-1 (primers: forward 5’-GACAGCACTGTCAGGGTCCATAG-3’ and 
reverse 5’-GCGGTCCTCCTTCACAAAGCTC-3’) in the skeletal muscle, liver and 
endothelial cells. We used β-actin (primers: forward 5’-
TCGTGGGCCGCTCTAGGCACCA-3’ and reverse 5’-
GTTGGCCTTAGGGTTCAGGGGGG-3’) as our reference gene. The qPCR was carried 
out using Quantifast SYBR Green master mix (Qiagen, Mississauga, ON) on a Mini-
opticon cycler (Bio-Rad, Mississauga, ON). We used the following cycling protocol: 
95°C for 5 min and then 40 cycles of 95°C for 10 s, 60°C for 30 s and 80°C for 30 s. 
SYBR green fluorescence was acquired at 80°C in each amplification cycle. 
Subsequently a melt curve was generated, starting at 60°C and taking measurements 
every 0.2°C until 95°C was reached.  
 
2.2.3 Protein content 
Skeletal muscle and liver were homogenized in sodium dodecyl sulfate (SDS) lysis buffer 
with protease inhibitor cocktail (Sigma-Aldrich). After centrifugation, protein 
concentrations were determined using a Bradford protein assay. Equal amounts of protein 
were loaded on a 10% polyacrylamide gel followed by gel electrophoresis and transfer to 
a PVDF membrane. The membrane was blocked with 3% bovine serum albumin 
overnight, followed by incubation with primary H-135 PAI-1 antibody and mouse anti-
rabbit horseradish peroxidase secondary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) for one hour each. The membrane was then treated with Western Lighting 
Chemiluminescence reagent (Perkin Elmer, Woodbridge, ON) and exposed to Kodak 
Biomax MR film (Carestream Health, Rochester, NY). We then stripped the membrane 
using stripping buffer and reprobed it for β-actin using anti-actin CP01 primary and IgM 
anti-mouse J1200 secondary antibodies (Calbiochem, La Jolla, CA). To determine the 
PAI-1 protein level in muscle homogenates by enzyme-linked immunosorbent assay 
(ELISA), we used muscle from mice where blood was flushed out with saline by means 
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of abdominal aortic cannulation and cutting of the vena cava. To determine the PAI-1 
protein level in plasma, we centrifuged systemic whole blood and used PAI-1 ELISA (for 
either total (all PAI-1 present in the sample including complexed with t-PA or u-PA) or 
active (only biologically active PAI-1 in the sample) PAI-1). PAI-1 ELISA kits were 
purchased from Innovative Research (Novi, MI). Finally, the plasmin anti-plasmin (PAP) 
complex level in plasma was measured with an ELISA kit from Cusabio Biotech 
(Newark, NJ). 
 
2.2.4 Fibrin zymography 
We used modified fibrin zymograph gels to examine the PAI-1 protein activity in skeletal 
muscle and liver tissues. Typically, the gel is prepared to include fibrinogen, 
plasminogen, thrombin and u-PA to induce plasmin-mediated fibrin degradation. The 
tissue sample is then run on the gel and the capacity of the PAI-1 in the sample to inhibit 
the u-PA-induced fibrin degradation is assessed (5). In the present study, instead of 
embedding u-PA in the gel, we mixed a known amount of u-PA with the sample and 
incubated the mixture for 5 minutes. We then ran this mixture, and u-PA alone, on 
separate lanes on the gel and assessed PAI-1 activity in the sample by comparing fibrin 
degradation caused by the mixture against degradation caused by u-PA alone. Again, the 
PAI-1 activity in the sample was revealed by inhibition of u-PA-induced fibrin 
degradation.  
Briefly, skeletal muscle and liver tissues were homogenized in Tris-NaCl-Triton-EDTA 
(TNTE) buffer. The homogenate (40 µl of total volume) including 50 µg of protein, 20 µl 
of non-denaturing loading buffer and 0.001 U of u-PA (all from Sigma-Aldrich) was 
resolved on a 10% SDS PAGE gel. To confirm the presence of fibrin in the gel (through 
its digestion), and as a method of standardization, 40 µl of homogenization buffer, 20 µl 
of non-denaturing loading buffer and 0.001 U of u-PA were mixed together and loaded in 
an empty lane on the gel.  The gel contained 1.2 mg/ml human fibrinogen (from 
Calbiochem), 0.06 U/ml human plasminogen and 0.25 U/ml human thrombin (both from 
Sigma-Aldrich). As human and mouse fibrinolytic factors have been demonstrated to 
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cross-react (5), human factors were used as a substitute for the extremely limited 
availability of comparable mouse fibrinolytic factors.  The SDS in the gel was exchanged 
with 2.5% Triton X-100 for 1 h. The gel was then incubated in developing buffer (30 mM 
Tris, 200 mM NaCl, pH 7.4) for 24 h (all from Sigma-Aldrich). The gel was stained with 
Coomassie blue R-250 (Bio-Rad) staining solution for 20 minutes, then destained and 
imaged on the Bio-Rad GS-690 imager. Densitometry was completed using the Multi-
Analyst 1.1 software package (Bio-Rad). 
 
2.2.5 Platelet count in septic blood 
We used heparanized blood samples diluted 200-fold in saline, labeled platelets therein 
with rhodamine 6G (0.4 µg/mL, Sigma-Aldrich) or calcein-AM (8 µM, Sigma-Aldrich) 
and counted them in a hemocytometer chamber under a microscope. 
 
2.2.6 Thrombelastography (TEG) 
Concurrently with the platelet count, TEG was used to measure coagulability in systemic 
blood. An aliquot of 360 µL of the heparinized systemic blood was added to a pre-
warmed heparinase cuvette of the TEG machine (type 5000, Hemonetics, Braintree, MA) 
and analyzed according to manufacturer’s instructions. In principle, TEG measures the 
developed mechanical strength of the formed blood clot after the onset of clotting, and it 
yields parameters reflecting the speed of clotting and the maximal clot strength (13).  
 
2.2.7 Statistical analysis 
Data are presented as mean ± SE; n indicates the number of mice per treatment. One 
skeletal muscle or liver sample was used per mouse. Data were analyzed using one-way 
ANOVA (repeated measures ANOVA for ex vivo model) followed by two-tail test with 
Bonferroni correction for multiple comparisons, with a level of significance of p < 0.05.   
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2.3 RESULTS 
 
2.3.1 Effect of streptokinase on capillary plugging 
Intravital microscopy at 7 h post-FIP showed that sepsis markedly increased the number 
of stopped-flow capillaries in the skeletal muscle (Figure 2.1). Streptokinase, a putative 
pro-fibrinolytic agent, reduced this number, suggesting that fibrinolysis plays a role in the 
restoration of capillary blood flow. Since ascorbate similarly reduced the number of 
stopped-flow capillaries (Figure 2.1), we pursued the testing of our hypothesis that 
ascorbate has a pro-fibrinolytic effect in the septic microvasculature. In principle, 
ascorbate could achieve this effect by elevating the local t-PA and u-PA levels and/or by 
inhibiting the local PAI-1. 
 
2.3.2 Effect of sepsis on pro-fibrinolytic factors in the skeletal muscle 
Sepsis did not statistically alter t-PA mRNA in skeletal muscle homogenate when 
compared to control; ascorbate did not affect the septic level of t-PA mRNA (P = 0.15, 
Figure 2.2a). Sepsis increased u-PA mRNA expression in muscle but ascorbate failed to 
alter this increased level (Figure 2.2b). This lack of effect of ascorbate was inconsistent 
with our hypothesized pro-fibrinolytic effect of ascorbate via increased u-PA level alone. 
Similar to the muscle homogenate, there was no effect of sepsis and ascorbate on t-PA 
mRNA in freshly isolated endothelial cells (major source of pro- and anti-fibrinolytic 
factors) (Figure 2.2a).  Sepsis increased u-PA mRNA in the endothelial isolates, but cells 
from septic mice treated with ascorbate failed to alter this increase (Figure 2.2b). 
 
2.3.3 Effect of sepsis on the anti-fibrinolytic factor PAI-1 
In muscle homogenates, sepsis increased PAI-1 mRNA when compared to control; 
ascorbate inhibited this increase (Figure 2.3a). In endothelial isolates, no effects of sepsis 
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Figure 2.1  Ascorbate and streptokinase reduce the sepsis-induced increase in 
stopped-flow capillaries.  Sepsis was induced by fecal injection into peritoneum (FIP). 
At 7 h post-FIP, the mouse hindlimb skeletal muscle capillary perfusion was observed 
using intravital microscopy. There was an increase in stopped-flow capillaries in septic 
mice. Ascorbate (10 mg/kg) or streptokinase (25000 U/kg), but not saline injected 
intravenously at 6 h reduced the blood flow stoppage in capillaries. * compared to 
control, # compared to sepsis+saline group, P < 0.05, n = 7 - 9 mice/group. 
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Figure 2.2. Effect of sepsis and ascorbate on t-PA and u-PA mRNA expression in 
mouse skeletal muscle. Panel a: Sepsis at 7 h did not affect t-PA mRNA in muscle 
homogenates or in endothelial isolates from this muscle. Panel b: Sepsis increased u-PA 
mRNA in the muscle and in cell isolates. Ascorbate injected at 6 h did not affect t-PA and 
u-PA mRNA levels. * P < 0.05 compared to control, ** P < 0.05 compared to cell isolate 
control, n = 8 - 11 mice/group for t-PA, 6 - 7/group for u-PA , and 6 - 7/group for cell 
isolates (both panels). 
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Figure 2.3.  Effect of sepsis and ascorbate on PAI-1 mRNA in mouse skeletal muscle, 
and on PAI-1 protein in muscle and blood plasma. Panel a: Ascorbate injected at 6 h 
inhibited the sepsis-induced increase in PAI-1 mRNA expression in muscle homogenates 
at 7 h. Based on western blot analysis (Panel b) or ELISA (Panel c), neither sepsis nor 
ascorbate affected PAI-1 protein expression in muscle homogenates. Panel d: Sepsis 
increased PAI-1 protein in systemic blood plasma analyzed by ELISA at 7 and 9 h post-
FIP. Ascorbate injected at 6 h did not affect these PAI-1 protein increases. * P < 0.01 
compared to control, # compared to sepsis+saline group, n = 8 - 9 mice/group for PAI-1 
homogenates, 3/group for immunoblots, 4 -5/group for ELISA, and 5 - 7/group for 
plasma. 
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or ascorbate were observed (Figure 2.3a).  Western blot and ELISA protein analyses of 
muscle homogenates showed no increase in PAI-1 protein expression in sepsis and no 
effect of ascorbate on protein levels (Figures 2.3b and 2.3c). Consistently, fibrin 
zymography of muscle homogenates showed no effect of sepsis and ascorbate on 
inhibition of u-PA-induced fibrin degradation (Figure 2.4a). However, total blood plasma 
PAI-1 protein analysis by ELISA revealed a nearly 3-fold increase in PAI-1 in septic 
mice at 7 h, and a 30-fold increase at 9 h. Ascorbate had no effect on these increases 
(Figure 2.3d). ELISA analysis of activated PAI-1 in septic mice at 7 h (See Chapter 3, 
Figure 3.3) showed a significant increase comparable to that of total PAI-1 protein shown 
in Figure 2.3d.  
 
2.3.4 PAI-1 expression in the liver 
Similar to published reports on PAI-1 mRNA in various organs (27, 35), our preliminary 
data in the septic mouse lung, heart, liver and kidney indicated that the liver is a major 
source of PAI-1 (See Chapter 3, Figure 3.2). Indeed, sepsis increased PAI-1 mRNA in the 
liver 6-fold, but only 2.5-fold in the skeletal muscle (Figures 2.3a, 2.6a). Ascorbate did 
not affect the PAI-1 mRNA expression in the liver (Figure 2.6a). Almost identical to the 
muscle western blot data (Figure 2.3b), our pilot western blots from liver homogenates 
showed no effect of sepsis or ascorbate on PAI-1 protein level (Figure 2.5). However, 
fibrin zymography of liver homogenates showed that sepsis increased the inhibition of u-
PA-induced fibrin degradation, while ascorbate failed to alter this effect (Figure 2.4b). 
Consistent with the dominance of liver in total PAI-1 production during sepsis, the liver 
homogenates showed a greater inhibition of u-PA-induced fibrin degradation than muscle 
homogenates (Figure 2.4c). 
 
2.3.5 Pro-fibrinolytic factor expression in the liver 
 In parallel to the increase in PAI-1 mRNA, t-PA mRNA and u-PA mRNA also increased 
in the septic liver (Figures 2.6b, 2.6c). In contrast to the muscle, ascorbate inhibited the 
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Figure 2.4. Effect of sepsis and ascorbate on PAI-1 protein activity in mouse skeletal 
muscle and liver analyzed by fibrin zymography. Panel a: Zymograph 1 shows an 
example of a fibrin zymograph gel used for analysis of PAI-1 activity in skeletal muscle 
homogenates. In lane 1, exogenous u-PA in loading buffer (40 µl total volume) was run 
on the gel. This u-PA resulted in plasmin-mediated fibrin degradation in the gel, seen as a 
bright band at 33 kDa. In lane 2, the control mouse muscle homogenate was mixed with 
the same amount of exogenous u-PA, and the mixture was run on the gel. When 
compared with lane 1, the band in lane 2 was dimmer, indicating inhibition of u-PA-
induced fibrin degradation (i.e., a measure of inhibition of exogenous u-PA by PAI-1 
present in the muscle sample). We used densitometry to set u-PA inhibition to 0 % when 
the sample band brightness was equal to that in lane 1, and to 100 % when the sample 
band brightness was equal to that of gel background. In lanes 3 and 4, we mixed u-PA 
with septic muscle homogenate from mice injected at 6 h with saline or ascorbate, 
respectively. Below zymograph 1, the 3 bars show a comparable u-PA inhibition among 
muscles from control, sepsis+saline and sepsis+ascorbate groups. Panel b: Zymograph 2 
shows an example of a fibrin zymograph in liver homogenates. With reference to lane 1, 
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a larger u-PA inhibition was seen in septic liver (lane 3) than in control liver (lane 2). 
Ascorbate treatment did not alter the sepsis-induced increase in u-PA inhibition. To 
compare PAI-1 activity between the muscle and liver (sepsis+saline groups), we ran an 
extra lane with liver in zymograph 1 (lane not shown) and compared this lane and lane 3 
with reference to lane 1. Panel c summarizes this comparison, showing a larger u-PA 
inhibition for septic liver than muscle. In each zymograph, the lanes were not run 
adjacent to each other. The spaces between lanes were cropped. * P < 0.05 compared to 
control, # P < 0.05 compared to septic muscle group, n = 5 - 6 mice/group. 
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Figure 2.5.  Effect of sepsis and ascorbate on the PAI-1 protein expression in the 
liver.  In a pilot experiment, mice were injected with saline or ascorbate at 6 h post-FIP.  
Neither sepsis nor ascorbate affected PAI-1 protein expression by western blotting in 
liver homogenates.  In the western blot, the lanes were not run side-by-side and therefore 
the lanes inbetween were cropped.  n = 2-3 mice/group. 
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Figure 2.6. Effect of sepsis and ascorbate on PAI-1 (Panel a), t-PA (Panel b), and u-
PA (Panel c) mRNA expression in mouse liver. Sepsis increased PAI-1, t-PA, and u-
PA mRNA expression. Ascorbate inhibited the increase in t-PA expression. * P < 0.05 
compared to control, # P < 0.05 compared to sepsis+saline group, n = 6 - 7 mice/group 
for PAI-1, 7 - 9/group for t-PA, and 7 - 9/group for u-PA. 
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sepsis-induced increase in t-PA mRNA in the liver (Figure 2.6b). However, the sepsis-
induced increase in u-PA mRNA was unaffected by ascorbate in the liver (Figure 2.6c).  
 
2.3.6 Plasmin anti-plasmin expression in the septic blood 
To determine whether the parallel increase in pro- and anti-fibrinolytic factors in liver 
mRNA resulted in an overall pro-fibrinolytic or anti-fibrinolytic effect, we used ELISA 
to measure the protein level of the PAP complex (an index of fibrinolysis by plasmin) in 
the systemic blood samples. Sepsis dramatically reduced the PAP level; ascorbate did not 
affect this response (Figure 2.7). 
 
2.3.7 Alterations in platelet count in the septic blood 
Analysis of systemic blood revealed a significant sepsis-induced 34 % drop in platelet 
count; ascorbate injection increased the platelet count by 23% when compared to the 
sepsis+saline group (Figure 2.8).  
 
2.3.8 Thrombelastography of septic blood 
Finally, we used TEG to measure coagulability in systemic arterial blood. Sepsis reduced 
the maximal clot strength at 6 h. Ascorbate injected at 5 h did not alter this clot strength 
(Figure 2.9 and Table 2.1).  
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Figure 2.7. Effect of sepsis and ascorbate on plasmin-antiplasmin (PAP) in systemic 
blood. Sepsis reduced PAP. Ascorbate did not affect this reduction. * P < 0.05 
compared to control, # P < 0.05 compared to the sepsis+saline group, n = 6 mice/group. 
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Figure 2.8. Effect of sepsis and ascorbate on platelet count.  Sepsis reduced the 
platelet count in mice.  Ascorbate partially restored the platelet count. * P < 0.05 
compared to control, # P < 0.05 compared to the sepsis+saline group, n = 8 mice/group 
for platelet count.
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Figure 2.9.  Examples of thrombelastography tracings from systemic blood samples 
obtained from control mice and septic mice at 6 h where saline was injected 
intravenously at 5 h.  R is the reaction time to initial clot formation, K is the kinetic time 
from the beginning of clot formation until the amplitude reaches 20 mm, α angle reflects 
the initial rate of force development (i.e., clotting speed) and MA is the maximum 
amplitude of clot strength. 
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Table 2.1. Summary of thrombelastography parameters from control, sepsis+saline, 
and sepsis+ascorbate groups (mean ± SE).  The TMRTG and MRTG have been 
estimated from the TEG tracing. 
  R 
(min) 
K 
(min) 
α angle  
(degrees) 
MA 
(mm) 
G 
(kd/s) 
TMRTG 
(min) 
MRTG 
(100*mm/s) 
control  
(n=5) 
13 ± 3  7 ± 1  33 ± 4  66 ± 2  10 ± 1  6 ± 2  6 ± 1 
sepsis+saline 
(n=5) 
17 ± 8  13 ± 5  23 ± 7  46 ± 5 *  5 ± 1 * 11 ± 6  5 ± 2 
sepsis+ascorbate 
(n=5) 
20 ± 5  11 ± 5  25 ± 6  47 ± 6 *  5 ± 1 * 7 ± 1  5 ± 1 
 
* P < 0.05 compared to control.  R - reaction time to initial clot formation, K - kinetic 
time from the beginning of clot formation until the amplitude reaches 20 mm, α angle - 
initial rate of force development, MA – maximum amplitude, G – shear elastic modulus 
strength, TMRTG – time to maximum rate of thrombus generation, MRTG - maximum 
rate of thrombus generation 
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2.4 DISCUSSION 
 
The present study employed a model of severe sepsis (80 % mortality at 24 h, (30)) 
associated with a marked drop in platelet count and systemic blood hypo-coagulability. 
The study examined for the first time the capillary bed perfusion in skeletal muscle in the 
context of consumption coagulopathy (i.e., DIC), including the role of fibrinolytic factors 
produced in the muscle and a mechanism of an antioxidant defense against capillary 
plugging through enhanced fibrinolysis. Analysis of the muscle tissue mRNA indicated 
that the antioxidant ascorbate did not affect the t-PA and u-PA levels in sepsis but it 
inhibited the PAI-1 level, resulting in a net pro-fibrinolytic effect in sepsis at the mRNA 
level. However, analyses of muscle and liver homogenates, and of systemic blood in 
septic mice, indicated no effect of ascorbate on (i) PAI-1 protein or its enzymatic activity, 
(ii) PAP protein, and (iii) blood hypo-coagulability assessed by TEG. Together, these 
results did not support the hypothesis that ascorbate promotes fibrinolysis in sepsis. 
 
2.4.1 Disseminated intravascular coagulation in the capillary bed 
DIC, a clinical condition in severe sepsis, has been explained by consumption 
coagulopathy where platelets and coagulation factors are depleted from systemic blood, 
resulting in a high risk for bleeding (11).  Importantly, decreasing systemic platelet count 
correlates with increasing mortality rate (17). To our knowledge, DIC has not been 
examined directly at the level of capillary bed. There is qualitative histological evidence 
of fibrin deposition in arterioles (11), but such deposition may not lead to stopped blood 
flow and trapping of coagulation factors in the septic microvasculature. We reported that 
sepsis stops flow in capillaries but not in the feeding arterioles or draining venules (25). 
Therefore, the capillary bed may represent a unique micro-environment in the context of 
DIC.  
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2.4.2 Methodological considerations 
Studies of sepsis are difficult given the complexity of the septic process itself (14) and 
the experimental shortcomings of animal models of sepsis. A considerable challenge is 
the animal-to-animal variability when determining the various end-points in sepsis (e.g., 
PAI-1 mRNA (7)). In the present study we aimed to reduce the variability of the 
fibrinolytic factors by studying septic mice whose capillary blood flow stoppage was at 
least 30 % (i.e., one standard deviation below the mean of 48 %, Figure 2.1). In spite of 
this step, the present study showed a large variability in fibrinolytic factors, including the 
variability in PAI-1 mRNA and protein expression (i.e., 5 to 7-fold differences between 
minimal and maximal values in particular groups, precluding reaching statistical 
significance between groups). This level of variability has been reported for mRNA of 
fibrinolytic factors (7).  The Ct values for the muscle and liver PAI-1 and β-actin were 
23.4 ± 0.3, 18.6 ± 0.7, 24.3 ± 0.6 and 18.0 ± 0.9, respectively.  The β-actin levels were 
observed to be similar between sham and septic groups. 
 
2.4.3 Pro-fibrinolytic factors in tissue 
Little is known about the pro-fibrinolytic factors in the septic microvasculature. The 
present data from muscle and liver (Figures 2.2a, 2.6b) agree with reports that sepsis 
either increases or causes no change in t-PA mRNA and protein levels in mice and rats 
(16, 21). The presently observed u-PA mRNA increases in muscle and liver homogenates 
of septic mice also agree with lipopolysaccharide (LPS)-induced increases in u-PA 
mRNA in various tissues in mice (35) and in sepsis-induced increases in u-PA plasma 
protein levels in humans (23).  
 
2.4.4 Anti-fibrinolytic factors in tissue 
Increased anti-fibrinolytic PAI-1 mRNA and protein expression have been reported for 
both septic patients (18) and animal models of sepsis (35). Our PAI-1 mRNA/ELISA 
protein data from plasma agree with these reports, but our PAI-1 protein data based on 
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western blot/ELISA analysis of tissue homogenates do not. We explain these data by 
noting that PAI-1 protein could be rapidly externalized and shed into blood stream (19), 
and/or released into blood from platelets (3), making the sepsis-induced increase in PAI-1 
protein preferentially detectable in blood plasma rather than in tissue.  
We used the fibrin zymography as an alternative approach to study the effect of sepsis on 
PAI-1 protein function. This approach does not measure PAI-1 activity directly, but 
rather it assesses the ability of PAI-1 in the homogenate to inhibit u-PA-induced fibrin 
degradation in the gel (10). Our zymographs showed that sepsis increased the inhibition 
of u-PA in the liver but not muscle (Figures 2.4a and 2.4b). This is consistent with the 
dominant role of liver in PAI-1 production during sepsis. However, in view of the data in 
Figure 2.4b, it is puzzling why western blot analysis failed to detect a sepsis-induced 
increase in PAI-1 protein even in this dominant organ. When considering the large 
change in PAI-1 mRNA detected by qPCR in the liver (Figure 2.6a), it is possible that the 
western blot in this tissue may not have been sensitive enough to detect the corresponding 
change at the protein level. Thus, the modest increase seen in PAI-1 mRNA in the muscle 
(Figure 2.6a) might have resulted in a corresponding protein change undetectable by 
western blot or zymography (Figure 2.4a).  Regarding the discrepancy between the effect 
of ascorbate on PAI-1 mRNA and protein expression, I discuss the possibility of a delay 
of the effect of ascorbate on the protein expression in blood plasma in section 5.2.4.   
 
2.4.5 Pro- versus anti-fibrinolytic factors in septic systemic blood 
Sepsis increases both u-PA and PAI-1 plasma protein levels (9). In humans injected with 
tumor necrosis factor (TNFα), the plasma PAP level rises but then it returns towards 
control (32), indicating a transient increase in fibrinolysis by plasmin in systemic blood. 
This transient characteristic of PAP could be due to the delayed surge of PAI-1 (31), the 
inhibitor of u-PA (9). In the present study we found that PAP level was markedly reduced 
at 7 h of sepsis (Figure 2.7), indicating that the large increase in plasma PAI-1 protein 
(Figure 2.3d) precipitated inhibition of fibrinolysis in systemic blood at this time.  
 
68 
2.4.6 Effect of ascorbate on fibrinolytic factors in sepsis 
We observed that ascorbate did not affect the sepsis-induced u-PA mRNA increase in the 
muscle or liver. However, ascorbate inhibited the sepsis-induced PAI-1 mRNA increase 
in the muscle but not liver. These findings are consistent with a pro-fibrinolytic effect of 
ascorbate in muscle (i.e., maintenance of elevated u-PA and lowering its inhibitor PAI-1). 
However, analyses of PAI-1 protein/enzymatic activity in muscle and liver homogenates, 
and of systemic blood in septic mice, indicated no effect of ascorbate. Thus, the protein 
data do not support the hypothesis that ascorbate promotes fibrinolysis during sepsis. 
 
2.4.7 Hyper-coagulation in the microcirculation versus hypo-
coagulation in systemic circulation in sepsis 
Severely septic patients with DIC present with a low platelet count (17), hypo-
coagulability of systemic blood as assessed by TEG, and high risk for bleeding (28). The 
present septic mice also showed lowered platelet count and TEG hypo-coagulability 
(Figures 2.8, 2.9 and Table 2.1). However, these observations disagree with our recent 
report of hyper-coagulability of blood in capillaries of skeletal muscle in septic mice, 
where increased platelet adhesion, fibrin deposition and propensity to form micro-
thrombi in these capillaries were noted (25). This apparent disagreement could be 
explained in terms of the concept of DIC where platelets and coagulation factors are 
trapped in the microcirculation and thereby depleted from systemic blood which then 
inevitably becomes hypo-coagulable. To our knowledge, however, this possible 
redistribution between micro- and macrocirculation during sepsis has not been addressed 
experimentally. There is some indirect evidence for this redistribution. Fisher and 
coworkers reported that FIP-injected mice demonstrated severe hypo-coagulability of 
systemic blood (TEG, prothrombin time, activated partial thromboplastin time measures), 
and that ascorbate injection completely protected against this hypo-coagulability (6).  
 In the present study, ascorbate reversed the low platelet count in sepsis toward the 
control level (Figure 2.8). We interpret these data to indicate that the observed beneficial 
effect of ascorbate (i.e., restoration of capillary blood flow in sepsis) could be at the level 
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of platelet adhesion rather than fibrinolysis. Recently, we showed that ascorbate reduces 
platelet aggregation and expression of the adhesion molecule P-selectin in an ex vivo 
model of sepsis (26). Clearly, there may be other mechanisms whereby ascorbate 
prevents/reverses capillary plugging (26, 34).  
 In conclusion, we hypothesized that 10 mg/kg ascorbate injection delayed for 6 h 
after the onset of sepsis has a fibrinolytic effect in the septic microvasculature. Based on 
the various approaches used to examine PAI-1 protein levels in plasma, and muscle and 
liver homogenates we failed to demonstrate any effect of the delayed ascorbate dose on 
these levels.  
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Chapter 3  
 
Ascorbate does not alter bacterial content, plasminogen 
activator inhibitor-1, and myeloperoxidase levels in septic 
mouse organs 
 
A version of this chapter has accepted for publication in Journal of Surgical Research 
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3.1 INTRODUCTION 
 
Sepsis, a systemic inflammatory response to an infection, has many detrimental effects on 
the cardiovascular system.  These include hypotension, reduced vascular reactivity and 
reduced capillary bed perfusion (19, 28, 31, 32).  The precise mechanism of reduced 
capillary perfusion is unknown, but an activated coagulation system including 
microthrombi formation in capillaries has been suggested (28, 29).  Sepsis elevates PAI-
1, which may lead to inhibited fibrinolysis and subsequent stabilization of microthrombi 
and plugging of capillaries (24, 30, 38).  However, data from PAI-1 knockout mice 
suggest elevated PAI-1 during sepsis may be beneficial as survival from sepsis was 
reduced in these knockout mice (13, 16). These studies indicate the complexity of the 
effects of sepsis on the coagulation system in various organs. 
 Sepsis is associated with marked reduction in plasma ascorbate (reduced form of 
vitamin C), which has been associated with poor outcome in sepsis (27).  Importantly, 
studies in mouse models of sepsis demonstrated that injection of an ascorbate bolus 
reduces organ injury and mortality in sepsis (8, 32, 34).  We have shown that ascorbate 
injection prevents and reverses capillary plugging in the septic mouse skeletal muscle by 
decreasing platelet activation and platelet-endothelial cell adhesion (28, 29, 32).  
Furthermore, antioxidant therapy in septic rats reduced organ dysfunction from oxidative 
damage caused by neutrophils, consistent with the beneficial effect of ascorbate (2).  
However, since ascorbate could alter the coagulation system (14, 29), the question arises 
as to whether it could negatively affect the beneficial role of PAI-1 in sepsis.  For 
example, Jaulmes and colleagues showed that PAI-1 expression depends on NADPH 
oxidase activity (14), which can be inhibited by ascorbate (33).  Given the apparent 
requirement for PAI-1 in survival during sepsis (16), ascorbate could thus indirectly 
reduce survival by inhibiting PAI-1.  Also, because PAI-1 is required for normal 
neutrophil efferocytosis (23) and infiltration (18), inhibition of PAI-1 by ascorbate could 
compromise the neutrophil-mediated immune response in infected organs.  Ascorbate has 
bactericidal properties at very high levels, raising the possibility that the reduced 
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mortality observed with ascorbate treatment could be due to reduced bacterial loads (12, 
37).  However, no apparent bactericidal effect of ascorbate in the peritoneum of septic 
mice has been reported (34).   
To investigate the mechanisms of action of ascorbate, our objective was to determine its 
effect on bacterial content, PAI-1 levels and neutrophil infiltration in septic mice.  Based 
on the fact that ascorbate reduces mortality in sepsis, and that PAI-1 is needed for 
survival, we hypothesized here that ascorbate does not alter the PAI-1 expression and 
neutrophil infiltration in organs with presumed high immune response in sepsis (lung, 
kidney, spleen, liver), preserving the beneficial effect from PAI-1. 
 
3.2 METHODS 
 
3.2.1 Animal model of sepsis   
All experiments were performed with approval of the University of Western Ontario 
Council on Animal Care.  Male C57BL/6 mice were bred in our animal facility from 
mice purchased from Jackson Laboratory (Bar Harbor, ME) or Charles River 
(Sherbrooke, QC), and were housed in a controlled environment with a 12 h light/dark 
cycle and access to food and water ad libitum.  The mice used were between 2-3 months 
old and between 20-25 g in weight.  Feces was collected from the cecum of donor mice 
and mixed in sterile saline at a concentration of 75 mg/ml and kept at 4°C.  Mice were 
anesthetized using a ketamine (80 mg/kg) and xylazine (4 mg/kg) mixture given via 
intraperitoneal injection.  Sepsis was induced in our mice by injecting the feces mixture 
into peritoneum (FIP) as described previously (32).  Alternatively, control sham mice 
were injected with 1 ml sterile saline intraperitoneally.  All mice were fluid resuscitated 
subcutaneously with 1 ml saline containing 2 µg/ml buprenorphine as an analgesic. 
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3.2.2 Experimental design   
We have reported that intravenous injection of ascorbate delayed to 6 h of sepsis (i.e., 
when capillary plugging is prevalent) restores capillary blood flow in skeletal muscle by 
7 h (28).  This restoration of flow (or reversal of plugging) could be due to dissolution of 
microthrombi through enhanced fibrinolysis due to inhibition of PAI-1 by ascorbate.  In 
the present study, we chose to study the effect of this delayed ascorbate injection.  At 6 h 
post-FIP, mice were anesthetized and then injected intravenously with 0.1 ml of sterile 
saline or ascorbate (10 mg/kg); they remained under anesthesia for 1 h.  Upon completion 
of the 1 hour treatment time (7 h post-FIP), the blood, peritoneal fluid, lung, kidney, 
spleen, liver, heart and the extensor digitorum longus skeletal muscle were harvested.  
We chose lung, kidney, spleen and liver because these organs were suspected to be 
involved in neutrophil recruitment and immune response during sepsis (1, 36).  We chose 
the skeletal muscle because in our previous studies we focused on the microcirculatory 
response of this organ during sepsis (28, 32); the heart presented another type of muscle 
to compare with skeletal muscle.  
 
3.2.3 Tissue and blood collection   
All chemicals were from Sigma-Aldrich (Oakville, ON) unless otherwise noted.  The 
carotid artery blood was collected 9:1 in acid citrate dextrose solution while peritoneal 
fluid was diluted with 2 ml sterile saline and collected to determine the bacterial load.  
The organs located in the peritoneum were washed twice with sterile saline to remove 
peritoneal fluid from their exterior.  Samples were stored in RNAlater for mRNA 
analysis, frozen at -80°C for protein analyses, or processed for assessing their bacterial 
content.  Samples were diluted 1:5 in sterile saline, homogenized, serially diluted in 10-
fold fashion, and plated on Columbia Blood Agar containing 5% sheep blood (MP0351, 
Oxoid, Nepean, ON) and grown overnight at 37°C.  The bacterial colony forming units 
(CFU) were counted and normalized to the CFU determined in the peritoneal fluid.   
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3.2.4 PAI-1 mRNA and protein quantification   
mRNA was isolated from homogenized tissues using Trizol (Invitrogen) and chloroform 
as directed by the manufacturer.  The isolated mRNA was reverse transcribed using 
Superscript II (Invitrogen), then quantified using Quantifast SYBR Green (Qiagen, 
Mississauga, ON) on a Bio-Rad CFX96 thermal cycler (Bio-Rad, Mississauga, ON).  The 
following primers were used to detect PAI-1: (primers: forward 5’-
GACAGCACTGTCAGGGTCCATAG-3’ and reverse 5’-
GCGGTCCTCCTTCACAAAGCTC-3’).  β-actin (primers: forward 5’-
TCGTGGGCCGCTCTAGGCACCA-3’ and reverse 5’-
GTTGGCCTTAGGGTTCAGGGGGG-3’) was used as a reference gene.  The following 
cycling protocol was used to amplify the target genes: 95°C for 5 min and then 40 cycles 
of 95°C for 10 s, 60°C for 30 s and 80°C for 30 s.   
 Blood in citrate was centrifuged at 6000g for 10 minutes and the plasma retained 
for active PAI-1 protein measurement by ELISA as directed by the manufacturer 
(MPAIKT, Molecular Innovations, Novi, MI).  PAI-1 enzymatic activity was determined 
by reverse fibrin zymography (5, 17).  Briefly, 10% SDS PAGE gels were impregnated 
with human fibrinogen (1.2 mg/ml, Calbiochem), 0.06 U/ml human plasminogen and 
0.25 U/ml human thrombin.  Tissues were homogenized in Tris-NaCl-Triton-EDTA 
buffer, 100 µg of protein was incubated for 5 minutes with 0.001 U exogenous u-PA, 
mixed with 20 µl of non-reducing loading buffer and run on the SDS PAGE gel.  The 
SDS in the gel was substituted with 2.5% Triton X-100 for 1 h, then developed for 24 h 
in developing buffer (30 mM Tris, 200 mM NaCl, pH 7.4).  Gels were stained with 
Coomassie blue then destained and densitometric analysis was conducted using Multi-
Analyst 1.1 software (Bio-Rad).   
 
3.2.5 Neutrophil infiltration in organs   
Neutrophil infiltration in organs was measured using a myeloperoxidase (MPO) assay, 
which is a conventional method for assessing this infiltration (22).  Frozen tissues were 
homogenized in 20 mM potassium phosphate buffer and centrifuged at 6000g for 20 
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minutes.  The supernatant was then discarded and the pellet was resuspended in 50 mM 
acetic acid with 0.5% hexadecyltrimethylammonium hydroxide detergent.  The samples 
were then sonicated for 10 s and centrifuged for 5 minutes.  The supernatants were mixed 
with a 1 mM TMB and 0.2 M acetic acid solution, warmed to 37°C, and the reaction 
initiated with the addition of 3 mM H2O2.  The samples were left to react for 5-30 
minutes (depending on the tissue), then quenched using 1000 U/ml beef catalase and 0.2 
M acetic acid.  Spectrophotometric analysis was conducted using the Model 680 
microplate reader and software version 5.2.1 (Bio-Rad) at 655 nm and compared to an 
MPO standard. 
 
3.2.6 Statistical analysis   
Data are presented as mean ± SE.  One sample of each organ was used per mouse.  
Statistical analysis was conducted using one-way ANOVA and the Bonferroni multiple 
comparison test.  Results were deemed significant with a P < 0.05. 
 
3.3 RESULTS 
 
3.3.1 Bacterial content  
Samples from sham peritoneal fluid showed zero or very low CFUs (0.002 ± 0.002 
CFU/µl (n = 13)), most likely resulting from occasional external contamination during 
sample collection/handling.  Septic mice had peritoneal fluid bacterial counts of 40,300 ± 
19,100 CFU/µl (n = 14).  We noted about a 7,000 fold range (with respect to the 
minimum and maximum counts) in these counts despite injecting each mouse with the 
same amount of feces.  When feces were grown separately on agar gels, the bacterial 
counts were 570 ± 190 CFU/µl of feces suspension (70 fold range with respect to the 
minimum and maximum counts).  Ascorbate injection at 6 h post-FIP did not 
significantly alter the peritoneal fluid bacterial count.  We observed that bacterial counts 
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were significantly increased in septic mouse blood and all organs compared to sham 
mice, with the highest mean count observed in the spleen and lowest in the muscle 
(Figure 3.1).  Ascorbate significantly lowered the bacterial count in the blood only.   
 
3.3.2 PAI-1 mRNA expression and enzymatic activity   
In control sham mice, the individual mRNA levels in organs were normalized to the 
mean mRNA level found in each organ.  Thus the normalized control levels were 1 ± 
0.18 (lung), 1 ± 0.29 (kidney), 1 ± 0.16 (spleen), 1 ± 0.76 (liver), 1 ± 0.16 (heart), and 1 ± 
0.14 (muscle).  Figure 3.2 shows the fold increase in PAI-1 mRNA expression (relative to 
the control level) in septic organs from mice treated with saline or ascorbate at 6 h post-
FIP.  We observed sepsis-induced increases in PAI-1 in the lung, kidney, spleen, liver 
and skeletal muscle.  Ascorbate lowered this increase only in the muscle.  Using an active 
PAI-1 ELISA, we determined that sepsis significantly increased the blood plasma active 
PAI-1 protein; ascorbate did not affect this increase (Figure 3.3).  Our preliminary 
experiments showed that the ELISA or western blotting approaches were insensitive to 
detect changes in PAI-1 protein in the organs.  For this reason, we used reverse fibrin 
zymography to indirectly measure PAI-1 enzymatic activity in an organ sample.  The 
PAI-1 activity in the sample mixed together with exogenous u-PA was assessed by the 
degree of inhibition of u-PA in terms of the degree digestion of the fibrin zymograph 
(Figure 3.4).  Figure 3.5 shows that sepsis increased u-PA inhibition in the lung, heart 
and liver samples, indicating increased PAI-1 activity in these organs.  Sepsis did not 
affect u-PA inhibition in the kidney, spleen and skeletal muscle.  Ascorbate did not affect 
the sepsis induced changes in u-PA inhibition in any organs (Figure 3.5).   
   
3.3.3 Neutrophil infiltration in organs     
Figure 3.6 shows that sepsis increased the MPO levels in the lung and liver, while the 
level was reduced in the spleen.  No change in the MPO level was observed in the heart,  
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Figure 3.1.  Increased bacterial content in septic mouse organs is not altered by 
ascorbate.  Sepsis was induced by feces injection into the peritoneum (FIP). At 6 h mice 
were injected i.v. with saline or ascorbate.  At 7 h post-FIP, the peritoneal fluid and 
carotid artery blood were collected, the organs harvested and homogenized, and then 
plated on Columbia blood agar and cultured for 18 h.  Bacterial content in fluids and 
organs in control sham mice was either zero or negligibly small (data not shown).  
Bacterial content in all septic fluids and organs significantly increased compared to 
control (P < 0.001).  Closed symbols are those of sepsis+saline mice, whereas open 
symbols are those of sepsis+ascorbate mice.  The bacterial content in septic blood was 
significantly reduced by ascorbate.  Several organ bacterial counts were calculated to be 0 
and are not included in the figure: two data points in the blood, lung, heart and muscle 
sepsis + saline groups, one in the kidney and liver sepsis + saline groups and two in the 
muscle sepsis + ascorbate group.  * P < 0.05 compared to sepsis + saline.  The P values 
for comparisons between sepsis + saline and sepsis + ascorbate groups were: 0.32 (lung), 
0.99 (kidney), 0.27 (spleen), 0.31 (liver), 0.23 (heart), and 0.21 (muscle).  The respective 
sample sizes for sham, sepsis + saline and sepsis + ascorbate groups were 13, 14, 15 
(blood), 13, 14, 15 (lung), 13, 14, 14 (kidney), 10, 11, 11 (spleen), 13, 15, 15 (liver), 13, 
14, 15 (heart), 13, 15, 15 (muscle) mice. 
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Figure 3.2.  Sepsis increases PAI-1 mRNA in organs.  Mice were treated as described 
in Figure 3.1 and RNA was quantified using real time qPCR.  The level of mRNA 
expression in control sham mouse organs was set to 1.  Fold increase in PAI-1 mRNA in 
the septic muscle was inhibited by ascorbate.  * P < 0.05 compared to control sham level.  
# P < 0.05 compared to sepsis + saline fold change.  The respective sample sizes for 
sham, sepsis + saline and sepsis + ascorbate groups were 5, 5, 6 (lung), 7, 6, 7 (kidney), 
8, 7, 8 (spleen), 8, 7, 7 (liver), 6, 5, 7 (heart), 8, 8, 9 (muscle) mice. 
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Figure 3.3.  Ascorbate does not affect increased PAI-1 protein in septic plasma.  
Active PAI-1 protein content in 7 h post-FIP septic mice was measured by ELISA.  There 
was no significant difference between sepsis + saline and sepsis + ascorbate.  * P < 0.05 
compared to control sham.  n = 4 mice per treatment. 
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Figure 3.4.  An example of reverse fibrin zymography of the mouse heart.  In u-PA 
lane, exogenous u-PA in loading buffer (40 µl total volume) was run on the gel. This 
resulted in a bright band at 33 kDa, due to plasmin-mediated fibrin degradation in the gel. 
In the sham lane, control sham mouse heart homogenate was mixed with an equal amount 
of exogenous u-PA, and the mixture was run on the gel. When compared with the u-PA 
lane, the sham band was darker, indicating inhibition of u-PA-induced fibrin degradation 
(i.e., measuring inhibition of exogenous u-PA by the PAI-1 in the sample). Densitometry 
was employed to set u-PA inhibition to 0 % when the band brightness was equal to that in 
the u-PA lane, and to 100 % when the brightness was equal to that of the background. In 
sepsis+saline and sepsis+ascorbate lanes, u-PA was mixed with septic heart homogenates 
from mice injected with saline or ascorbate, respectively. 
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Figure 3.5.  Sepsis increases PAI-1 activity in the lung, heart and liver.  PAI-1 
enzymatic activity in septic mice at 7 h was measured indirectly by reverse fibrin 
zymography.  There were no significant differences between sepsis+saline and sham and 
between sepsis+saline and sepsis+ascorbate groups in the spleen.  * P < 0.05 compared to 
sham.  The respective sample sizes were 5 (lung, muscle), 6 (liver), 7 (heart), 8 (kidney) 
and 9 (spleen) mice. 
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Figure 3.6.  Ascorbate does not affect sepsis-induced increase in lung MPO activity, 
nor decrease in spleen MPO activity.  Neutrophil infiltration was determined through 
an MPO assay in septic organs at 7 h, with saline or ascorbate treatment at 6 h.  
Ascorbate did not affect MPO activity in any organ compared to sepsis + saline.   * P < 
0.05 compared to control sham.  The respective sample sizes for sham, sepsis + saline 
and sepsis + ascorbate groups were 10, 9, 9 (lung), 6, 6, 6 (spleen), 6, 6, 6 (liver), 4, 5, 5 
(heart) mice. 
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while the kidney and skeletal muscle samples yielded undetectable MPO levels.  
Ascorbate did not alter the MPO level in any organ (Figure 3.6).  
 
3.3.4 Relationship between MPO level and PAI-1 activity   
Figure 3.7 plots the MPO values of Figure 3.6 against the PAI-1 activity data of Figure 
3.5.  There was a high linear correlation between these two data sets (slope is 
significantly different from 0, R2 value = 0.79).  When muscle and kidney data were 
removed (due to inability to detect MPO), the R2 value was 0.75; however the slope was 
not significantly different due to the reduced sample size.  It should be noted that MPO 
and PAI-1 activity measurements were not always collected from the same mice and 
therefore I had to construct Figure 3.7 using the mean values of MPO and PAI-1 activity.   
 
3.4 DISCUSSION 
An intravenous ascorbate dose of 10 mg/kg (equivalent to approximately 700 mg in an 
average human male) has been shown to improve capillary perfusion in septic mouse 
skeletal muscle (28, 29, 32).  This dose of ascorbate is clinically relevant as humans have 
been treated with higher doses through parenteral nutrition (20).  In the present study, we 
found that this ascorbate treatment does not affect the bacterial content in the lung, heart, 
kidney, spleen, liver or skeletal muscle, or PAI-1 mRNA expression/enzymatic activity 
and neutrophil infiltration in septic mice.  These results support our hypothesis that, in 
parallel to the beneficial effect on capillary bed perfusion, ascorbate does not alter sepsis-
induced increases in PAI-1 expression and neutrophil infiltration in the organs with high 
immune response, preserving the beneficial effect of PAI-1 on the immune function. 
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Figure 3.7.   MPO content correlates with PAI-1 activity in septic mouse organs.  
The mean fold change in MPO from all sepsis+saline mouse organs in Figure 3.6 was 
plotted against the mean fold change in PAI-1 activity from Figure 3.5.  Panel A: The 
slope of the linear regression for sepsis+saline was significantly different from 0.  The 
fold change in MPO signals for muscle and kidney were set to 1 (MPO levels were 
undetectable in these two organs). These results suggest that neutrophil recruitment is 
related to the PAI-1 activity.  Panel B: When muscle and kidney were removed from the 
linear regression due to the inability to detect MPO, the R2 value was relatively 
unchanged, however there were too few points for statistical analysis. 
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3.4.1 Model of ascorbate administration in sepsis   
The low ascorbate levels observed in septic patients (i.e., levels linked to poor outcome 
(27)), can be reversed by parenteral nutrition containing large doses of ascorbate (1000- 
3000 mg/day) (20, 27).  We and others have shown that a large dose of ascorbate (200 
mg/kg) injected into mice at the onset of sepsis protects against the various detrimental 
effects of sepsis, including high mortality (8, 9, 34, 35).  We also showed that a lower 
dose of ascorbate (10 mg/kg) has similar beneficial effects against sepsis and that these 
effects are seen even when ascorbate injection is delayed six hours into sepsis (28, 32).  
The model of delayed injection is clinically relevant for patients presenting with sepsis, 
and therefore this model was chosen to study the effect of ascorbate in the present 
investigation. 
 
3.4.2 Methodological considerations   
To our knowledge, this study characterized for the first time the effect of FIP on bacterial 
content in the peritoneal fluid and various organs.  This characterization was limited to 
bacteria which grow on agar plates, including Escherichia, Staphylococcus and 
Streptococcus bacterial strains (Certificate of Analysis, Oxoid).  Surprisingly, despite 
ensuring injection of identical amounts of feces solution into mice, there was a large 
variability in the bacterial content of the peritoneal fluid at 7 h post-FIP (7,000 fold 
range).  Accordingly, the bacterial counts in organs also varied extensively 
(approximately 100 fold range for each organ, Figure 3.1).   This extensive mouse to 
mouse variability has been observed in other models of sepsis (13, 26).  We speculate 
that the large variability in our FIP model was due to differences in the viability and type 
of the bacteria in the feces solution (70 fold), variability in the local immune response at 
the site of injection and in the spread of bacteria from the peritoneum to the blood and 
organs.  Clearly, the observed variability in the initiation of sepsis contributed to the 
variability seen in the PAI-1 mRNA levels (Figure 3.2).  This particular mRNA 
variability is also consistent with the literature (10, 24).  Regarding detection of 
sepsis/ascorbate-induced changes in PAI-1 protein level in the various organs, for 
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unknown reasons, our attempts to determine these changes by western blotting and 
ELISA failed.  We speculate that the inability to detect differences in PAI-1 protein 
levels was due to the high basal levels of PAI-1 found in the non-vascular cells drowning 
out the relatively small increase in PAI-1 in the vascular cells.  Therefore, we used fibrin 
zymography, where exogenous u-PA inhibition is an indirect measure of PAI-1 activity 
in organ samples.  The fibrin zymography detected sepsis-induced increases in PAI-1 
activity in blood plasma, lung, heart and liver (Figure 3.5, 3.8 and 3.9). 
 
3.4.3 Bacterial counts in septic organs   
Among the organs studied, the highest levels of bacteria were found in the organs that 
mount the greatest immune response (kidney, spleen and liver), while relatively few 
bacteria were found in the skeletal muscle (Figure 3.1).  Blood was also heavily infected 
with bacteria (Figure 3.1).  The lack of effect of ascorbate on peritoneal fluid bacterial 
count is consistent with the reported lack of effect of ascorbate on this count in the septic 
mouse (34).  Previous reports have observed a bactericidal effect of ascorbate (3, 12, 37).  
We speculate that the discrepancy between the effect of ascorbate on bacterial count in 
blood (Figure 3.1) and peritoneal fluid could be due to a possible bactericidal 
concentration of ascorbate in the blood post-intravenous injection..   
  
3.4.4 PAI-1 expression and activity in organs   
Sepsis-induced increases in PAI-1 mRNA expression in the lung, kidney and liver 
(Figure 3.2) are consistent with increases reported by Raeven and colleagues (24).  
Others have also observed increased PAI-1 mRNA expression in organs with high 
immune activity during sepsis (25, 26).  Ascorbate did not affect the increases in PAI-1 
mRNA in the organs with high immune activity, but it inhibited the increase in PAI-1 
mRNA in the skeletal muscle (Figure 3.2).  It is possible that the effect of ascorbate on 
PAI-1 mRNA expression differs depending on the immune activity in each organ.  To our  
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exogenous   
u-PA           Sham 1        Sepsis 1       Sham 2       Sepsis 2 Sham 3    Sepsis 3
% exogenous u-PA inhibition            0 30                 63                -15                64                 -40              21  
Figure 3.8. An example of reverse fibrin zymography of the mouse blood plasma.  
Similar to the reverse fibrin zymography in Figure 3.4, exogenous u-PA was added to 
blood plasma from 3 control sham mice (Sham 1, 2 and 3) and 3 sepsis + saline mice 
(Sepsis 1, 2 and 3).  Sham 1 and Sepsis 1, 2 and 3 lanes were darker than the exogenous 
u-PA lane, indicating inhibition of exogenous u-PA by PAI-1 in these samples.  Sham 2 
and 3 had brighter bands than the exogenous u-PA band, indicating enhanced fibrin 
degradation than by exogenous u-PA alone, most likely due to endogenous u-PA present 
in these sham samples.  According to the definition of exogenous u-PA inhibition in 
Figure 3.4, negative values of u-PA inhibition were computed.  Side by side comparison 
between septic and sham mice clearly shows greater inhibition of exogenous u-PA in the 
septic samples. 
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Figure 3.9.  Sepsis significantly increases u-PA inhibition in the blood plasma.  These 
data summarize the mouse blood plasma reverse fibrin zymography data exemplified in 
Figure 3.8.  These data agree with data from Figure 3.3, where an Active PAI-1 ELISA 
showed a significant increase in PAI-1 protein expression in the blood plasma of septic 
mice.  A negative u-PA inhibition indicates a pro-fibrinolytic state, and a positive u-PA 
inhibition indicates an anti-fibrinolytic state in the blood plasma.  These data then 
validate the use of reverse fibrin zymography to detect PAI-1 in samples. * P < 0.05 
compared to sham.  n = 6 mice per group. 
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knowledge, the effect of ascorbate or other antioxidants on PAI-1 mRNA/protein 
expression in septic organs has not been reported. 
     Our data showing sepsis-induced increases in active PAI-1 protein in blood 
plasma (Figure 3.3) are consistent with previous reports (31).  Ascorbate did not affect 
this increase.  Our preliminary unpublished data at 9 h post-FIP (ascorbate injected at 6 h) 
also showed a lack of effect of ascorbate on sepsis-induced increase in PAI-1 protein, 
indicating that even at 3 h post-injection, ascorbate does not affect PAI-1 protein 
expression.  Regarding PAI-1 enzymatic activity in organs measured by zymography, 
ascorbate did not alter the levels observed during sepsis (Figure 3.5).  Out of the six 
organs examined, the sepsis-induced increased PAI-1 mRNA levels yielded increased 
activities only in the lung and liver.  The lack of increased enzymatic activity, despite 
increased mRNA level in the kidney and skeletal muscle, suggests several possibilities 
including decreased mRNA stability resulting in no PAI-1 protein production in certain 
organs or an organ specific post-translational modification of PAI-1 protein in sepsis.  
Interestingly, the PAI-1 activity in the septic heart increased despite unchanged mRNA 
level in this organ. We speculate that PAI-1 protein in septic blood coursing through the 
richly vascularized heart affected the PAI-1 activity assessed by zymography in this 
organ.   
 
3.4.5 Immune response during sepsis.   
Increased MPO content has been reported in septic organs including the lung and liver (6, 
21).  Our data in Figure 3.6 (lung and liver) agree with these reports.  The lack of MPO 
signal in the kidney under sham conditions is consistent with the literature (15).  Sepsis 
reduced the MPO content in the spleen and did not change in the heart (Figure 3.6) 
consistent with the trends observed by Gebska and colleagues (11).  To explain the 
reduced MPO content in the spleen, we speculate that the large number of neutrophils in 
sham control mouse spleen (associated with the largest MPO signal, Figure 3.6) was 
reduced in sepsis due to neutrophil recruitment from the blood into organs such as lung 
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and liver.  Ascorbate had no effect on the sepsis-induced MPO content in any organ 
(Figure 3.6). 
The correlation in Figure 3.7 suggests a dependence of the MPO signal on PAI-1 activity.  
Previously, the level of neutrophils in blood was shown to depend on the PAI-1 protein 
content (23).  This dependence and the correlation shown in Figure 3.7 suggest that PAI-
1 may play a role in the immune response during sepsis. 
 
3.4.6 Significance of the lack of effect of ascorbate.   
We reported that delayed ascorbate bolus rapidly reverses (i.e., within 1 h) capillary 
plugging in sepsis.  The present data indicate that this effect is not due to ascorbate 
promoting fibrinolysis of microthrombi (i.e., by ascorbate inhibiting PAI-1) in capillaries 
in the skeletal muscle.  The reversal of capillary plugging could be due to other 
mechanisms through which ascorbate exerts its effect rapidly (e.g., ascorbate reduces 
platelet aggregation and platelet-endothelial adhesion (28, 29)).   
 Ascorbate did not appear to affect the bacterial counts in the various organs 
within 1 h post-injection.  This observation is consistent with the report that short-term 
ascorbate treatment failed to change the rate of superoxide production by neutrophils (7) 
indicating that bacterial killing by neutrophil respiratory burst is not affected by 
ascorbate.  Furthermore, administration of 320 mg/kg ascorbate over 2 h did not affect 
the intracellular concentration of ascorbate in leukocytes (4).  We speculate that the lack 
of short-term effect of ascorbate on bacterial count is of little consequence, because 
bacteria in the various organs could be killed by leukocytes infiltrating these organs 
during sepsis.  
The lack of effects of ascorbate at 10 mg/kg in the present study does not preclude any 
effects of ascorbate given at larger doses or at different time points (e.g., at the onset of 
sepsis or for longer treatment periods).  These effects could be subject to future 
investigations. 
 
96 
 In conclusion, we have demonstrated that ascorbate does not affect bacterial 
content, PAI-1 or MPO in organs with high immune activity.  These results suggest that 
the beneficial effect of ascorbate on capillary bed perfusion is not accompanied by effects 
of ascorbate on the fibrinolytic or immune responses in septic organs. 
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Chapter 4  
 
Effect of ascorbate on plasminogen activator inhibitor 1 
expression and release from platelets and endothelial cells 
in an in-vitro model of sepsis  
 
A version of this chapter has been submitted to Microcirculation. 
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4.1 INTRODUCTION 
Sepsis, a systemic inflammatory response to an infection, leads to numerous 
physiological abnormalities, including a fibrinolytic abnormality due to elevated plasma 
levels of the PAI-1 (11, 12, 24).  The fibrinolytic abnormality could be critical at the 
microcirculatory level because elevated PAI-1 levels could inhibit the plasmin-mediated 
dissolving of microthrombi and thus contribute to DIC. To this end, we have shown that 
sepsis causes plugging of the capillary bed, involving increased occurrence of both fibrin 
plaques and platelet adhesion/aggregation in capillaries (22, 28, 29). To our knowledge, 
the role of the fibrinolytic abnormality in sepsis-induced capillary plugging is not known. 
We have reported that, in septic mice, an intravenous injection of ascorbate delayed 6 h 
after the onset of sepsis unplugs capillaries.  Although numerous mechanisms could 
explain this beneficial effect of ascorbate (22), it is possible that ascorbate enhances the 
dissolving of capillary microthrombi by inhibiting PAI-1, to account for the observed 
unplugging of capillaries.  Oxidative stress has been implicated in the increase in both 
mRNA and protein expression of PAI-1 in endothelial cells (8).   
Because endothelial cells and platelets (i.e., cells in the milieu of capillary microthrombi) 
can release PAI-1into the extracellular space (2, 16, 21), the objective of the present 
study was to use a simple in vitro and ex vivo models of sepsis to examine whether 
ascorbate affects PAI-1 expression and release from these two cell types.  We 
hypothesized here that ascorbate reduces the expression and release of PAI-1 in 
endothelial cells or platelets in sepsis.  Because the beneficial effect of ascorbate against 
capillary plugging has been shown to depend on eNOS-derived NO (22), we also 
hypothesized that the PAI-1 release is NO-dependent.  
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4.2 METHODS 
4.2.1 Animal preparation 
All experiments were conducted under protocols approved by the University of Western 
Ontario Council on Animal Care.  Endothelial cells for in vitro experiments were 
obtained from male wild type C57BL/6 mice (age: 1.5 – 3 months) from Charles River 
Laboratories (Sherbrooke, Quebec, Canada).  Preliminary experiments indicated no 
gender specific differences in platelet function, therefore platelets for ex vivo experiments 
were obtained from male or female wild type mice of the same strain.  Mice were 
anesthetized with ketamine (80 mg/kg) and xylazine (4 mg/kg) prior to cell harvest or 
platelet collection.  All supplies were purchased from Sigma Aldrich (Oakville, ON, 
Canada) unless otherwise stated. 
 
4.2.2 In-vitro model of sepsis in cultured endothelial cells 
Endothelial cells were harvested from the whole hind limb skeletal muscle as previously 
described (1, 15).   We have chosen this tissue because sepsis-induced capillary plugging 
and the beneficial effect of ascorbate against this plugging has been observed in the 
mouse skeletal muscle (22, 26).  The muscle was excised, cut into 2 mm diameter pieces 
and digested in 25 mls of digestion solution containing 21 mg collagenase, 3 mg dispase, 
3 mg trypsin and 41 mg bovine serum albumin for 30 minutes.  The digest was strained 
through nylon mesh, centrifuged at 805 rcf for 5 minutes, then the pellet was resuspended 
in culture medium containing 20% fetal bovine serum, heparin (5 U/ml), endothelial 
growth supplement (100 µl/ml), antibiotic-antimycotic solution (10µl/ml) and L-
glutamine (0.1 µg/ml) in DMEM/F12 HAM.  The endothelial cells were grown to 
confluence and then were purified using a GS-I lectin coated magnetic bead 
immunoseparation.   This method has been demonstrated to yield nearly 100% pure 
endothelial cells as assessed by vWF (1).  We randomly chose cell lines to test for vWF 
to confirm continued specificity of this method.  The cells were cultured and used for 
experiments up to passage 10.  For each experiment, cells were grown to confluence and 
treated with ascorbate (100 µM) for 1, 3, 6 or 24 hours, concurrently with either 
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lipopolysaccharide (LPS) (10 µg/ml) or tumor necrosis factor alpha (TNFα) (10 ng/ml).  
We used 100 µM  ascorbate as it has been demonstrated to raise the intracellular 
ascorbate content to approximately 5 mM, a physiologically relevant concentration in 
vivo (31).  The doses of LPS and TNFα were chosen as they were demonstrated to induce 
platelet-endothelial cell adhesion, suggesting activation of the coagulatory pathway (32).  
Alternatively, cells were treated with thrombin (0.0375 U/ml) for 3 - 5 minutes at the end 
of the 24 hour period.  We used LPS and TNFα as conventional agents of sepsis as these 
substances have been shown to initiate endotoxemia in vivo (6, 7).  The chosen dose of 
ascorbate results in physiological levels of intracellular ascorbate (31).  Thrombin 
(0.0375 U/ml) has been used to activate platelets to mimic sepsis ex-vivo (23).  We have 
used this concentration of thrombin in endothelial cells as an alternative in vivo model of 
sepsis (23).  After completion of experiments, cell supernatants were collected and 
frozen, and the cells were lysed in Tris-NaCl-Triton-EDTA (TNTE) buffer or Trizol 
(Invitrogen, Burlington, ON, Canada). 
 
4.2.3 Ex-vivo model of sepsis in isolated platelets 
Blood was collected 9:1 in acid citrate dextrose solution and platelets were isolated as 
detailed previously (23).  Briefly, the blood was centrifuged at 179 rcf, the supernatant 
was retained and centrifuged at 774 rcf to pellet the platelets.  The platelet pellet was 
resuspended in DPBS, divided evenly among the treatment groups and stimulated with 
thrombin (0.0375 or 0.075 U/ml), LPS (10 µg/ml) or TNFα (10 ng/ml) with or without 
ascorbate (100, 500 or 1000 µM).  To ensure autoactivation of the platlets did not occur, 
a control unstimulated platelet fraction was always included for each individual 
experiment.  The platelets were incubated at 37°C for 5 or 10 minutes, then centrifuged to 
pellet the platelets.  The supernatant was retained and frozen, and the platelet pellet 
homogenized in TNTE buffer or Trizol.  To determine the effect of NO on platelets, the 
NO donor S-Nitroso-N-acetylpenicillamine (SNAP) (1 µM) was used in conjunction with 
thrombin (0.0375 U/ml).  This level of SNAP inhibits thrombin-induced aggregation of 
platelets ex-vivo (23). 
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4.2.4 PAI-1 mRNA expression 
mRNA was isolated using the phenol-chloroform extraction method.  The isolated 
mRNA was purified using DNAse I and Reverse Transcribed using Superscript II 
(Invitrogen).  The mRNA was quantified using Quantifast SYBR Green (Qiagen, 
Mississauga, ON, Canada) as directed on a Bio-Rad CFX96 thermal cycler (Bio-Rad, 
Mississauga, ON, Canada).  The primers used to detect the mRNA are as follows: PAI-1 
(forward: 5’-GACAGCACTGTCAGGGTCCATAG-3’ and reverse: 5’-
GCGGTCCTCCTTCACAAAGCTC-3’) and β-actin as a housekeeping gene (forward: 
5’-TCGTGGGCCGCTCTAGGCACCA-3’and reverse: 5’-
GTTGGCCTTAGGGTTCAGGGGGG-3’).  The mRNA was amplified using the 
following cycling protocol: 95°C for 5 min and then 40 cycles of 95°C for 10 s, 60°C for 
30 s and 80°C for 30 s. 
 
4.2.5 PAI-1 protein content and release 
Both intracellular PAI-1 protein (i.e., PAI-1 in cell lysates) and PAI-1 release (i.e., PAI-1 
in cell supernatants) were quantified using the total PAI-1 ELISA Kit (IMPAIKT-TOT, 
Innovative Research, Novi, MI) according to manufacturers directions.  The ELISA can 
detect PAI-1 within the 0.05 – 50 ng/ml range.  Accordingly, endothelial cell samples 
were diluted with TNTE buffer prior to being added to the ELISA plates. 
 
4.2.6 Statistical analysis 
Data are presented as mean ± SE.  A minimum of five different cell lines were used for 
the endothelial cell experiments.  A minimum of four groups of pooled platelets were 
used for the platelet experiments.  Statistical analysis was performed using a repeated 
measures one-way ANOVA and the Bonferroni multiple comparison test.  Results are 
significant with a P < 0.05. 
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4.3 RESULTS 
 
4.3.1 Endothelial cell PAI-1 mRNA and protein expression   
mRNA analysis of endothelial cell PAI-1 expression revealed that LPS and TNFα raised 
expression after 6 and 24 h of stimulation, but not after 1 and 3 h of stimulation, when 
compared with control unstimulated cells (Figure 4.1).  Ascorbate had no effect on the 
expression of PAI-1 mRNA at 1- 6 h, but there was a tendency for increased PAI-1 
mRNA in TNFα groups at 24 h.  Interestingly, the LPS- or TNFα-induced increase in 
mRNA seen at 6 and 24 h did not translate into increased production of PAI-1 protein at 
24 h (Figure 4.2a).  Surprisingly, in control cells, ascorbate increased the production of 
PAI-1 protein.  In LPS- or TNFα-treated cells, ascorbate had no effect on PAI-1 protein 
(Figure 4.2a).   
 
4.3.2 PAI-1 protein release from endothelial cells  
For all control, LPS and TNFα groups at 24 h, the level PAI-1 protein release was greater 
than the level of PAI-1 protein remaining in the cells (Figure 4.2b).  Ascorbate did not 
affect the PAI-1 release in any of the groups (Figure 4.2b).  Figure 4.3a shows the effect 
of acute stimulation of endothelial cells with thrombin.   Thrombin had no effect on intra-
endothelial PAI-1 protein in control cells treated with either vehicle or ascorbate for 24 h 
(Figure 4.3a) nor on PAI-1 protein release from these cells (Figure 4.3b).  
 
4.3.3  PAI-1 protein release from platelets  
Figure 4.4 shows that neither LPS nor TNFα affected intracellular and released PAI-1 
protein levels when compared to the control unstimulated platelets.  However, as 
anticipated, thrombin at a concentration of 0.0375 U/ml, reduced intracellular PAI-1 and 
elevated released PAI-1 protein levels from platelets (Figure 4.5).  Ascorbate (100 µM) 
did not affect these levels.  However, ascorbate at 500 µM and 1000 µM inhibited the 
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Figure 4.1.  Increases in PAI-1 mRNA expression after 6 and 24 hours of endotoxin 
stimulation were not altered by ascorbate.  Isolated endothelial cells were stimulated 
with either LPS (10 µg/ml) or TNFα (10 ng/ml) for 1, 3, 6 or 24 hours as indicated.  Cells 
were treated with 100 µM ascorbate (Asc) or media (Con) concurrently.  Total cell 
mRNA was extracted, reverse transcribed and PAI-1 mRNA was quantified using qPCR.  
Neither LPS nor TNFα altered the PAI-1 mRNA expression at 1 hour (A) or 3 hours (B).  
In contrast, at 6 (C) and 24 hours (D) there was a significant increase in PAI-1 expression 
with both LPS and TNFα treatment.  Ascorbate did not appear to have an effect on this 
increase in PAI-1 expression. * P < 0.05 compared to control.  n = 4 – 9 different cell 
lines per treatment. 
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Figure 4.2.  Stimulation with LPS or TNFα did not alter the PAI-1 production or 
release in endothelial cells.  Endothelial cells were stimulated with LPS (10 µg/ml) or 
TNFα (10 ng/ml) for 24 hours, the supernatant was collected and the cells lysed.  The 
PAI-1 content in the cells and released in the supernatant were quantified using an 
ELISA.  Ascorbate (Asc, 100 µM) treatment alone for 24 hours significantly increased 
the PAI-1 production in the endothelial cells over media alone (Con).  Co-treatment with 
either LPS or TNFα eliminated the observed increase in PAI-1 protein.  No stimulation 
altered the PAI-1 release into the supernatant.  * P < 0.05 compared to control.  n = 4 cell 
lines per group. 
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Figure 4.3.  Thrombin has no acute effect on the release of PAI-1 protein from 
endothelial cells.  Endothelial cells previously treated with ascorbate (Asc, 100 µM) or 
fresh media (Con) for 24 hours were stimulated with thrombin (0.0375 U/ml) for five 
minutes, then the supernatant was collected and the cells lysed.  Thrombin had no effect 
on the release of PAI-1 into the supernatant.  Ascorbate treatment significantly increased 
the PAI-1 production intracellularly.  * P < 0.05 compared to control.  n = 5 cell lines per 
group. 
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Figure 4.4.  PAI-1 release by platelets is not induced by LPS or TNFα.  Platelets were 
isolated from whole mouse blood, stimulated with LPS (10 µg/ml) or TNFα (10 ng/ml) 
for 10 minutes, then the supernatant and platelet pellets were collected and subjected to 
ELISA.  Neither LPS nor TNFα treatment caused release of PAI-1 from the platelets into 
the supernatant.  n = 6 platelet isolations per group. 
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Figure 4.5.  Ascorbate (Asc) does not inhibit thrombin induced PAI-1 release from 
platelets.  Isolated platelets were treated with ascorbate (100 µM) or DPBS, followed by 
stimulation with thrombin (0.0375 U/ml) for 10 minutes, then supernatant and platelet 
pellets were collected and subjected to ELISA.  Thrombin induced a significant release of 
PAI-1 from the platelets into the supernatant.  Ascorbate had no effect on the thrombin 
induced PAI-1 release.  * P < 0.05 compared to control.  n = 5 platelet isolations per 
group. 
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thrombin-induced PAI-1 release from platelets (Figure 4.6).  As the pH of unbuffered 
ascorbate is acidic, we tested whether this inhibition is pH-sensitive.  Figure 4.7 shows 
that buffered ascorbate solution (1000 µM, pH adjusted to 7.2) failed to inhibit the 
thrombin-induced platelet PAI-1 release.  When the pH was lowered with hydrochloric 
acid to the same level as unbuffered ascorbate (pH 5.8 and 3.8), similar reductions in 
platelet PAI-1 release were observed (Figure 4.8). 
 
4.3.4 Platelet PAI-1 protein release, dependence on NO  
Platelet activation by thrombin and the protective effect of ascorbate in the 
microvasculature have both been reported to be NO-dependent (22, 23).  Figure 4.9 
shows that the thrombin-induced release of PAI-1 was independent of exogenous NO 
(i.e., 5 min treatment with SNAP). Since this treatment has been shown to inhibit 
thrombin-induced platelet aggregation (23), the results in this figure suggest that the 
platelet PAI-1 release is independent of NO. 
 
4.4 DISCUSSION 
In the present study, we have shown that the PAI-1 production and release by the 
endothelial cells and platelets in vitro/ex vivo is not affected by low dose (100 µM) 
ascorbate treatment.  Additionally, we have uncovered a potential pH-mediated 
mechanism whereby ascorbate may be able to inhibit platelet PAI-1 release.  We also 
explored the NO dependence of the platelet PAI-1 release and determined that platelet 
PAI-1 release may not be NO-dependent. 
 We have previously shown that an intravenous bolus of ascorbate can decrease 
capillary plugging, resulting in improved organ function and improved survival (22, 27, 
29).  A persistent challenge we have faced is the complexity of the in vivo model of 
sepsis and the limitations in measuring PAI-1 protein release directly into the blood by 
both endothelial cells and platelets at the capillary level.  The present study uses 
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Figure 4.6.  High dose ascorbate inhibits the thrombin induced PAI-1 release from 
platelets.  Platelets were treated with unbuffered ascorbate (500 and 1000 µM) or DPBS, 
followed by stimulation with thrombin (0.0375 U/ml) for 10 minutes.  PAI-1 in the 
supernatant and platelet pellet was quantified using ELISA.  Thrombin induced a 
significant release of PAI-1 from the platelets into the supernatant.  Both 500 and 1000 
µM doses of ascorbate significantly reduced the release of PAI-1.  * P < 0.05 compared 
to control.  # P < 0.05 compared to thrombin stimulated platelets.  n = 6 platelet isolations 
per group. 
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Figure 4.7.  pH buffered high dose ascorbate (Asc) does not inhibit the thrombin 
induced platelet PAI-1 release.  Isolated platelets were treated with ascorbate (1000 
µM) buffered to pH 7.2 or DPBS, followed by stimulation with thrombin (0.0375 U/ml) 
for 10 minutes.  PAI-1 was then determined in the supernatant and platelet lysate by 
ELISA.  Thrombin induced a significant increase in PAI-1 release by platelets into the 
supernatant.  Ascorbate had no effect on the thrombin induced PAI-1 release.  * P < 0.05 
compared to control. n = 4 platelet isolations per group. 
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Figure 4.8.  Thrombin-induced platelet PAI-1 release is inhibited by low pH.  
Isolated platelets were suspended in DPBS at either pH 7.4, 5.8 or 3.8, followed by 
stimulation with thrombin (0.0375 U/ml) for 10 minutes.  PAI-1 protein level was then 
determined in the supernatant and platelet lysate by ELISA.  Thrombin induced a 
significant increase in PAI-1 release by platelets into the supernatant.  Low pH generated 
a dose-dependent inhibition of the thrombin induced PAI-1 release.  * P < 0.05 compared 
to control.  # P < 0.05 compared to thrombin at pH 7.4.  n = 3 platelet isolations per 
group. 
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Figure 4.9.  Effect of thrombin on PAI-1 release from platelets subjected to 
exogenous NO.  Platelets were isolated and treated with the NO donor SNAP (1 µM) or 
DPBS, and thrombin (0.0375 U/ml).  SNAP did not alter the thrombin-induced platelet 
PAI-1 release.  * P < 0.05 compared to both control and SNAP only treatments.  n = 4-5 
platelet isolations per group. 
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 simplified in vitro and ex vivo models to examine the effect of the antioxidant ascorbate 
on PAI-1 production and release in cells that would be in a very close proximity to a 
developing microthrombus in vivo. 
 
4.4.1  PAI-1 mRNA expression in endothelial cells 
Our findings that endothelial cell PAI-1 mRNA is not altered after 1 or 3 h LPS/TNFα 
treatment are in contrast to the PAI-1 increase reported soon after endotoxin treatment 
(18).  Interestingly, the increase in PAI-1 mRNA observed at 6 and 24 h mirrored that of 
several previous studies (18, 19).  It is possible that inter-species differences between 
mouse and human cells may be responsible for the delayed response to LPS.  Indeed, it 
has been reported that humans have a markedly increased sensitivity to LPS compared to 
mice, and that inter-species differences in sensitivity to infections can have profound 
effects on survival (6, 14).  Ascorbate did not appear to have any effect on PAI-1 mRNA 
expression after 1- 6 h of treatment (Figure 4.1).  Ascorbate tended to potentiate the 
TNFα-induced increase in PAI-1 mRNA (Figure 4.1d).   
 
4.4.2 PAI-1 protein expression and release in endothelial cells 
The tendency of increased PAI-1 mRNA observed upon ascorbate treatment in control 
cells translated into increased PAI-1 protein production (Figure 4.2a).  Interestingly, this 
increase in protein production did not lead to increased release into the extracellular 
space.  Additionally, treatment with LPS or TNFα largely abolished the ascorbate-
induced increase in PAI-1 protein expression.  It cannot be ruled out that the large 
amount of PAI-1 released over 24 hours has masked an increase in PAI-1 release late in 
the treatment period (i.e., if treatment increased release beginning at 23 h, 1 h of 
increased release may be masked by the first 23 h of release).  Consistent with these 
findings, thrombin also did not initiate increased release of PAI-1 (Figure 4.3).  The 
findings of Figure 4.2 support the notion that endothelial cells make a significant 
contribution to the total PAI-1 in the vasculature.  The lack of increase in PAI-1 protein 
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levels upon LPS stimulation are in contrast with previous studies in human umbilical vein 
endothelial cells, where significant increases in PAI-1 were observed (18, 19).  Given the 
demonstrated inter-species variability, it is conceivable that the expression profile of PAI-
1 in mouse cells differs from that of human cells.   
 
4.4.3 Effect of ascorbate on PAI-1 protein expression 
Regarding the ascorbate-initiated increase in PAI-1 protein production, it is unclear what 
mechanism is involved in this phenomenon. However, we speculate that ascorbate either 
increases the stability of PAI-1 enhancing the total content, or it is acting as a stimulant to 
the initiation of the non-fibrinolytic effects of PAI-1 (e.g., angiogenesis).  It would be 
interesting to determine what effect intravenous ascorbate might have on the vasculature 
of healthy individuals.   
Overall, the long time period required for ascorbate to induce any changes in the 
endothelial cells (e.g., 24 h may be needed for increased PAI-1 production) argues 
against ascorbate’s acute effects on fibrinolysis.  Thus, in the septic microvasculature, 
restoring capillary blood flow by ascorbate over 1 h period may not occur through PAI-1 
inhibition.  Interestingly, the increased survival during sepsis seen after ascorbate 
injection suggests that increased or maintained PAI-1 production during sepsis may not 
be detrimental to the outcome of sepsis.  Despite studies suggesting PAI-1 is essential to 
survival from sepsis, it is unclear how PAI-1 is beneficial (9). 
 
4.4.4 PAI-1 release from platelets 
Consistent with our previous findings of the lack of effect of LPS/TNFα on platelet 
aggregation (23), in the present study, LPS and TNFα did not alter platelet PAI-1 release.  
This finding agrees with previous work using platelets isolated from mice using both LPS 
(20) and TNFα (3), though others have observed spontaneous platelet activation upon 
LPS stimulation (4).  It is important to note that these conflicting studies were conducted 
with platelets from species other than mice, suggesting inter-species differences may be 
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involved in the different responses.  It is also possible that neither LPS nor TNFα directly 
stimulate platelets, but rather they may stimulate the production of other signaling 
molecules (i.e., thrombin) that ultimately activate platelets (10).  The present ex vivo 
model may lack the cells necessary for the production of these signaling molecules.   
The observed PAI-1 release from platelets upon short-term stimulation with thrombin 
agrees with the literature (2, 16).  Ascorbate at a concentration of 100 µM did not alter 
the release of PAI-1 from platelets.  This is in contrast to our previous report that 
ascorbate reduces the rate of thrombin-induced aggregation (23).  It is possible that we 
were unable to observe a reduction in the rate of PAI-1 release due to our inability to 
measure PAI-1 content in real time.   We observed a trend towards enhanced PAI-1 
release with ascorbate treatment (Figures 4.5 and 4.7).  This trend suggests that PAI-1 
release may not be directly tied to platelet aggregation.   
 
4.4.5 pH dependent effect of ascorbate on PAI-1 expression 
Interestingly, treatment with 500 and 1000 µM ascorbate at an unbuffered pH 
significantly inhibited platelet PAI-1 release (Figure 4.6).  We observed that alteration of 
pH alone yielded similar inhibition of platelet PAI-1 release (Figure 4.8).  This response 
was abolished when the pH of ascorbate was adjusted to 7.2 (Figure 4.7).  Critically ill 
patients can develop severe acidosis, where the blood pH drops below 6.8 (17), and this 
level may reach as low as 6.0 in localized regions, particularly during ischemia (5).  
Although this level is higher than the pH measured in the current study (pH 5.8 at 500 
µM and pH 3.8 at 1000 µM), there was a trend of increasing inhibition with increasing 
dose of ascorbate (Figure 4.6).  It is possible that lower levels of unbuffered ascorbate 
would give a physiological pH, while still inhibiting the release of PAI-1 from platelets.  
Consistent with our findings of a potential pH dependence of ascorbate, it has been 
reported that thrombin-induced platelet adhesion is reduced by approximately 25% at pH 
7.0 and 50% at pH 6.5 (5).  Our preliminary experiments with control sham mice showed 
that injected ascorbate (10 mg/kg) dropped the blood pH from 7.2 to 7.0 at 5 min post-
injection.  Thus, our buffered ascorbate solution in the platelet experiments mimicked the 
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blood’s capacity to buffer ascorbate, and indicated that the observed inhibition of 
thrombin-induced PAI-1 release by ascorbate may not occur under normal physiological 
conditions in vivo. Given the propensity for acidosis during sepsis, we speculate that as 
the blood pH in septic mice treated with ascorbate may be lower than that in sham mice, 
it is conceivable that a modest pH dependent reduction in platelet activation and PAI-1 
release occurs in our septic mouse in vivo model (Chapters 2 and 3).  
 
4.4.6 NO-dependence of PAI-1 release in platelets  
Ascorbate has been demonstrated to act in an eNOS dependent manner in vivo (13, 22, 
23, 25, 26).  In the present study, we showed that addition of the NO donor SNAP does 
not affect the thrombin-induced platelet PAI-1 release.  Previously it was demonstrated 
that SNAP at the same concentration reduces the rate of thrombin-induced aggregation 
(23).  We speculate that the PAI-1 release and the aggregation reflect the different 
signaling pathways initiated by the thrombin stimulus (16, 30). 
 In conclusion, we have confirmed the presence and release of PAI-1 protein by 
both endothelial cells and platelets, two cell types in close proximity to a developing 
intravascular microthrombus.  This local PAI-1 may be critical in the 
development/stability of the thrombus in sepsis.  Ascorbate may reduce the PAI-1 release 
through a pH-dependent mechanism, thus destabilizing the thrombus and promote 
restoration of blood flow through plugged capillaries.  This potential mechanism warrants 
further investigation. 
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Chapter 5  
 
DISCUSSION 
 
5.1 SUMMARY 
 
Fibrinolysis is a key component in the maintenance of the normal coagulation process, 
allowing for the dissolution and removal of unneeded clots in the body.  During sepsis, 
capillary blood flow is reduced involving activated coagulation and microthrombi 
formation in capillaries.  Concurrently, fibrinolysis is impaired, stabilizing microthrombi.  
However, a potential link between reduced blood flow and impaired fibrinolysis has yet 
to be addressed.  Ascorbate has been suggested as a potential treatment for sepsis, as it 
has been demonstrated to improve capillary blood flow during sepsis. The mechanism of 
the protective effect remains largely unknown.  Given these effects, I hypothesized in 
Chapter 2 that the capillary plugging observed in sepsis was a result of reduced 
fibrinolysis, and that ascorbate is protective by increasing fibrinolysis through inhibition 
of PAI-1.  The results of this study are presented in Chapter 2. 
 As bacteria are found in the blood of septic patients, there is the potential that the 
spread of bacteria among organs through systemic circulation could be reduced by the 
impaired capillary blood flow and subsequent increased trapping of bacteria within the 
organ(s) initially containing the most bacteria.  Thus, increased PAI-1 levels during 
sepsis may actually play a beneficial role by reducing bacterial spread and by promoting 
the local immune response in this organ(s).  For these reasons, I hypothesized in Chapter 
3 that ascorbate would not alter the bacterial content, PAI-1 expression or neutrophil 
recruitment in “immunogenic” organs of mice.  Results supporting this hypothesis are 
presented in Chapter 3. 
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 During sepsis, platelets become activated due to the excessive thrombin 
expression along with other coagulation proteins.  Platelets treated with ascorbate have 
been demonstrated to have reduced activation and granule secretion.  As platelet derived 
PAI-1 is released through α-granule secretion, I hypothesized in Chapter 4 that ascorbate 
treatment reduces the platelet PAI-1 expression in response to thrombin stimulation.  The 
results of this study are outlined in Chapter 4. 
 To support the notion that ascorbate acts in a pro-fibrinolytic manner, I showed in 
Chapter 2 that streptokinase, a fibrinolytic agent, restored the capillary flow to a similar 
degree to that of ascorbate.  Next, to determine whether fibrinolysis was indeed altered, I 
studied the mRNA expression of the plasminogen activators t-PA and u-PA, and their 
inhibitor PAI-1, during sepsis.  The mRNA expression of t-PA and u-PA were not altered 
by ascorbate treatment.  Interestingly, the mRNA expression of PAI-1 in the skeletal 
muscle of septic mice was reduced by ascorbate treatment, suggesting an overall 
enhancement of fibrinolysis with ascorbate treatment.  Unfortunately, the increase in 
PAI-1 mRNA expression did not translate into increased PAI-1 protein as measured by 
western blot, ELISA or zymography.  Given this discrepancy, I then determined whether 
there was a difference in mRNA expression between skeletal muscle and liver.  
Ascorbate did not alter the mRNA expression of u-PA or PAI-1, however t-PA 
expression was dramatically reduced, suggesting a reduction in fibrinolysis.  The increase 
in PAI-1 expression during sepsis, and the lack of effect by ascorbate, was confirmed by 
zymography.  The plasmin anti-plasmin levels were severely reduced, suggesting a lack 
of plasmin, likely due to an overall anti-fibrinolytic state.  These results failed to support 
the hypothesis that ascorbate reduces PAI-1, thereby increasing fibrinolysis. 
 As PAI-1 is not altered by ascorbate, I then wondered if it is beneficial to 
maintain increased levels of PAI-1 in different organs of the body.  First, I confirmed that 
sepsis significantly increased the bacterial content in all organs, while treatment with 
ascorbate reduced the bacteria in the blood only.  Next, I determined that PAI-1 mRNA is 
increased in all septic organs studied except the heart.  Among these organs, ascorbate 
reduced the mRNA expression in the skeletal muscle only.  Increased PAI-1 protein 
levels were confirmed in the blood plasma, lung, heart and liver by zymography, while 
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ascorbate had no effect in any organ.  Neutrophil content in the organs was increased in 
the lung and liver, and decreased in the spleen.  Ascorbate did not have any effect on 
neutrophil content.  These results support the hypothesis that ascorbate does not alter (i) 
the bacterial content, (ii) PAI-1 expression and (iii) neutrophil infiltration in the tissues 
during sepsis, suggesting that ascorbate has no effect on the immune response during 
sepsis. 
 As it is impossible to examine individual cell types in in vivo models, I next 
aimed to determine whether the endothelial cells and platelets, two cell types in direct 
contact with the blood, have altered PAI-1 expression under septic conditions.  I 
confirmed that long-term exposure to a sepsis-like state increases PAI-1 mRNA 
expression.  In contrast to Chapters 2 and 3, the increase in PAI-1 mRNA did not 
translate into increased PAI-1 protein expression or release by endothelial cells.  
Interestingly, I determined that ascorbate alone increases PAI-1 protein expression, but 
that neither endotoxins nor the coagulation activator thrombin initiated the release of this 
PAI-1.  Next, I showed that thrombin, but not endotoxins, induced PAI-1 release from 
platelets, and that ascorbate inhibited this release through a pH dependent mechanism.  
Finally, I showed that the thrombin-induced platelet PAI-1 release is independent of 
nitric oxide/eNOS.  These results partially support my hypothesis that ascorbate inhibits 
the sepsis-induced increase in PAI-1 production/release, through the discovery of a pH 
mediated mechanism.  The finding that the inhibition of PAI-1 release by ascorbate is NO 
independent does not support my hypothesis.  These findings support the previous in vivo 
studies that ascorbate does not affect PAI-1 expression/release under normal 
physiological conditions. 
 In conclusion, the evidence presented in this thesis demonstrates that the sepsis-
induced capillary plugging may be perpetuated because of an anti-fibrinolytic 
environment.  The beneficial effect of ascorbate on restoring capillary perfusion likely 
does not involve alterations in the anti-fibrinolytic state present in the septic 
microvasculature. 
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5.2 GENERAL DISCUSSION  
 
5.2.1 Comparison of the models of sepsis 
The complexity of the septic process makes it a difficult disease to study.  To date, 
numerous mediators and cell types have been implicated in the pathology of the 
inflammatory process characteristic of sepsis.  A key confounding factor in studying 
sepsis in humans is the presence of numerous different underlying medical conditions and 
characteristics present prior to the onset of sepsis in the majority of patients (12).  These 
other diseases (e.g., cancer, diabetes) and factors such as age often alter the septic 
condition and change the outcome (62).  Despite the complexity of sepsis in the clinical 
setting, animal models have been used to address the various aspects of the septic process 
(15, 18, 63).  The present thesis encompasses three distinct types of models of sepsis, in 
vivo, in vitro, and ex vivo, to study the fibrinolytic system in the capillaries in relation to 
sepsis.  The relationship between sepsis and fibrinolytic factor content, bacterial load and 
immune response was explored using an in vivo model.  The release of PAI-1 from 
endothelial cells and the mRNA levels of fibrinolytic factors in these cells were studied 
using an in vitro model and the release of PAI-1 from platelets was studied using an ex 
vivo model.  Though all models used have limitations, they were used in conjunction to 
elucidate how ascorbate improves capillary perfusion during sepsis. 
 
5.2.1.1 In vivo models of sepsis 
 The endotoxemia models most often involve administration of a bolus of 
lipopolysaccharide (LPS) from the Gram-negative bacteria wall, but alternative models 
have used initiators such as peptidoglycan, a component of the Gram-positive bacterial 
wall, and other components elevated during sepsis (15).  These components initiate the 
production of inflammatory cytokines including tumor necrosis factor alpha (TNFα), 
interferon gamma (IFNγ) and various interleukins (51).  The major advantage of the 
endotoxemia model is the ease in which the experiment can be standardized (11).  
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Though easily standardized, the use of the endotoxemia model has a major limitation in 
its lack of clinical relevance, as endotoxins do not accurately mimic bacteria, due to the 
non-replicating nature of cytokines (11), the inability of LPS to mimic Gram-positive 
bacteria, (18) and the fact that LPS levels are generally low in septic humans (63). 
 Bacterial models are considered to be the most physiologically accurate, as the 
initiation of sepsis is through a bacterial mechanism similar to that of human patients.  
Direct injection of a known amount of purified bacterial culture, known as a bacteremia 
model, is the most easily standardized of the three bacterial models (11).  Unfortunately, 
often the bacteria are killed by the immune system prior to replication; therefore the 
model does not accurately mimic the septic response to an infection (9, 18).  Should the 
bacteria be destroyed, this model largely reverts to an endotoxemia model from the 
cytokines produced initially, with the drawbacks discussed above. 
 The remaining two models, CLP and FIP are both based on the same principle, 
namely they mimic a peritonitis model of sepsis initiated by a bowel perforation.  As the 
bacteria introduced are more numerous both in type and quantity, they sustain cytokine 
production comparable to that seen in septic patients.  Potentially the most biologically 
accurate model is CLP, where the cecum is ligated to form a bowel obstruction, and is 
then perforated with a needle.  This method allows for a slow release of fecal matter into 
the peritoneal cavity, and as a result a relatively slow onset to polymicrobial sepsis that 
fairly accurately mimics that observed in human patients (11).  The cytokine release is 
lower and sustained over a longer period, similar to that observed in septic patients (63).  
In addition, using different gauge needles, the severity of sepsis can be controlled, 
allowing for the study of different degrees of perforation and different time points 
depending on the length of survival for the particular perforation size.  The major 
disadvantages of the CLP model is the high variability in severity of sepsis depending on 
surgical skill, and the potential for abscess formation around the site of puncture, 
preventing the fecal matter from escaping from the cecum (15).  These two factors 
contribute to a high degree of variability between one animal and the next, and between 
the surgical personnel.  The necessity to conduct sham operations on control animals 
further detracts from this model, as any surgery causes cytokine release into the blood 
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stream, and surgery also has an inherent risk of introducing infection.  This leads to the 
possibility that some control sham animals may also develop sepsis. 
 The last common model of sepsis is the FIP model, where fecal matter is directly 
injected into the peritoneal cavity of the mouse.  Like the CLP model, the FIP model 
generates a polymicrobial sepsis similar to that seen in human patients (52).  The FIP 
model relies less on the skill of the experimenter, as it is a simple procedure to inject 
feces into the peritoneal cavity.  In addition, like CLP it is possible to alter the severity by 
injecting different concentrations of feces.  While it is possible for sham mice to become 
septic due to inadvertent bowel perforation while administering the intraperitoneal dose 
of sterile saline (to accurately mimic the fluid loading and physical effects on the 
peritoneum), this is less likely than in CLP as it is much less invasive.  Unfortunately, 
there are drawbacks to the FIP model, including the possibility of abscess formation 
around the fecal injection and the possibility of injecting the feces subcutaneously instead 
of into the peritoneal cavity.  In addition, the sudden injection of feces is less accurate 
than the CLP model at mimicking sepsis in humans, as it does not allow for a slow 
cytokine release in response to a slowly increasing bacterial load (18).  It is also possible 
that the collection of feces from a donor animal and suspension in saline may 
preferentially select for some types of bacteria over others (in particular, the anaerobic 
bacteria may not flourish in an aerobic environment), as over 70 different species of 
bacteria are present in a typical fecal slurry (52).   
 In the present studies, the FIP model of sepsis was chosen as a compromise to 
balance enhanced reproducibility with a polymicrobial sepsis model, while maintaining a 
model closely mimicking human sepsis. 
 
5.2.1.2 Methodological limitations 
Research using animal model of sepsis is also difficult due to the methodological 
limitations inherent in these models.  As a result, simplified models are constantly being 
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developed to attempt to cope with these difficulties.  In the present studies, I have 
employed in vivo, in vitro and ex vivo models to mimic particular aspects of sepsis. 
 The in vivo model of sepsis is generally regarded as the most physiologically and 
pathologically relevant.  The various different in vivo models are detailed above (see 
section 5.2.1.1).  While using the FIP model of sepsis, I encountered one constant 
confounding issue, the high degree of inter-individual variability between one animal and 
the next.  Despite using exactly the same protocol in inducing sepsis, I still observed a 
7,000 fold difference in the number of bacteria in the peritoneal fluid of septic mice (see 
Chapter 3).  This enormous range in infection has likely contributed to the variability 
observed in the other experimental parameters explored in Chapters 2 and 3.  The 
possibility that a protective effect of ascorbate is masked by the large variability in the 
FIP model cannot be discounted.  I have tried to reduce this possibility by using several 
different techniques where feasible (i.e., using qPCR, ELISA and zymography to study 
PAI-1).  Another limitation is the inability to isolate the response from individual cell 
types in the whole organ homogenate.  It is entirely possible that alterations in protein 
expression in the endothelial cells that line the blood vessels were masked by the proteins 
present in the surrounding tissues collected in the whole tissue sampling.  For this reason, 
I also used an in vitro endothelial cell model. 
 The in vitro model employed in the present studies was a purified skeletal muscle 
microvascular endothelial cell line.  Using this model I was able to directly measure 
mRNA and protein expression in endothelial cells alone.  Although this method allows 
one to zoom at the cellular level, the major drawbacks that I encountered were the 
difficulty in mimicking sepsis, and the possibility of cell phenotype changing under 
culturing conditions.  I used cytokines known to play a role in the septic pathophysiology, 
and applied them to an established in vitro model of microvascular endothelial cells.  In 
addition, I have obtained primary endothelial cell cultures from septic mice as a hybrid 
model that includes the characteristics from the in vivo model.  The hybrid model allows 
examination of mRNA expression from a single cell type as in the in vitro models (see 
Chapter 2).  Unfortunately due to the small number of cells obtained, this model was not 
conducive to the determination of protein expression. 
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 To study platelets, I employed an ex vivo model.  The model involved removing 
platelets from mice and subjecting them to various chemicals to elicit responses.  As 
platelets are a small component of the body, altered platelet protein expression might be 
hidden by protein expressed in the tissue cells.  Major drawbacks of the platelet ex vivo 
model are that (i) similar to in vitro models, sepsis is difficult to model here, and (ii) 
platelets by nature tend to activate and aggregate in response to being removed from the 
body.  Similar to the in vitro model, I used established methods of mimicking sepsis. I 
also used great care to prevent platelet activation and used the appropriate controls to 
determine when autoactivation occurred.   
 In addition to the limitations of the models, there were other methodological 
issues.  I noted a lack of sensitivity to detect changes in PAI-1 protein using western 
blotting and ELISA.  As I was able to use ELISAs to observe increases in PAI-1 protein 
levels in blood plasma, it seems that the most likely source of lack of sensitivity was the 
high basal levels in non-vascular cells masking a modest increase in PAI-1 in the 
vasculature.   Due to the inability to detect PAI-1 protein levels directly, I instead had to 
rely on an alternative method using reverse fibrin zymography.  The zymography 
employed was modified from published methods of fibrin zymography (7, 27) with one 
major alteration being the addition of exogenous u-PA.  This allowed for the indirect 
measurement of PAI-1 activity through the inhibition of the exogenous u-PA.  As PAI-1 
is reported to be responsible for virtually all of the inhibition of u-PA (45), this method 
has been used as an indicator of PAI-1 activity (and indirectly PAI-1 content, see 
Chapters 2 and 3).  Reverse fibrin zymography on mouse blood plasma mirrored the 
active PAI-1 protein detected by ELISA, validating this method.  As there are two 
plasminogen activators that are inhibited by PAI-1, u-PA and t-PA, it is possible that the 
levels of PAI-1 are actually under-reported in the present studies due to some inhibition 
of endogenous u-PA and t-PA.  It is difficult to eliminate this possibility.  However, 
through the use of a known amount of exogenous u-PA, this method gives a measure of 
the free PAI-1 (total PAI-1 minus PAI-1 reacting with endogenous t-PA and u-PA), and 
therefore gives a total measure of the anti-fibrinolytic potential of the tissue.  Although 
the various models used had limitations and drawbacks, I have used these models in 
conjunction with each other to test my hypotheses.    
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5.2.2 Capillary plugging during sepsis 
Sepsis causes many alterations to the vascular system, including hypotension, reduced 
vascular reactivity and reduced capillary perfusion (2, 6, 56, 61).  It has been reported 
that sepsis can reduce capillary perfusion in the skeletal muscle to the point where less 
than half of all capillaries have blood flowing through them (57).  This impairment of 
capillary flow has been observed in other animal models of sepsis, in their various septic 
organs, and in septic patients (4, 5).  The exact mechanism of this reduction in perfusion 
remains elusive, with several possibilities, including a narrowing of the capillary lumen 
preventing red blood cell flow, stiffening of red blood cells causing them to become 
lodged in the capillary, the lodging of leukocytes in the vasculature preventing blood 
flow, closing of precapillary sphincters preventing flow to certain capillaries and the 
formation of microthrombi that occlude the capillaries (3, 24, 25, 34, 49).  Recent 
evidence lends support to the notion that microthrombi formation contributes partially to 
this phenomenon, namely that fibrin was observed in the septic capillaries, and that 
depletion of platelets or inhibition of the coagulation cascade partially restored capillary 
perfusion (49).  This partial restoration suggests that another mechanism is also involved 
in the capillary plugging other than platelet adhesion and coagulation.  That decreased 
fibrinolysis contributes to this phenomenon is a possibility, given that PAI-1 protein 
expression is increased during sepsis (33, 55).  Increased PAI-1 would only serve to 
further enhance the stability of the fibrin and, in conjunction with platelet adhesion, 
increased PAI-1could lead to the formation of stable microthrombi that plug the 
capillaries.   
 It has been reported that red blood cells exhibit reduced deformability during 
sepsis (3).  Stiffer red cells in conjunction with platelet adhesion and fibrin deposition 
may serve to enhance the capillary occlusion leading to the cessation of blood flow.  
Leukocytes have been observed to adhere to the endothelium during sepsis (24, 34).  The 
contribution leukocyte adhesion has to capillary plugging is unclear as adhesion has 
almost exclusively been observed in the post-capillary venules only (49).  The vascular 
reactivity has also been observed to decrease during sepsis (35).  The loss of vascular 
reactivity serves to further derange the blood flow to the capillaries, as the arterioles 
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cannot properly maintain optimal blood flow velocity through contraction and relaxation. 
However, the plugging of capillaries in sepsis cannot be explained solely in terms of 
closed venules or arterioles, because plugged capillaries have been observed even when 
their feeding arterioles and draining venules were patent and perfused with blood (49).  A 
recent study observed a narrowing of the capillary lumen consistent with what might be 
termed a capillary sphincter (25).  It is important to note that this narrowing only 
occurred sporadically in capillaries in the skin.  The implication of this finding on deeper 
tissue capillaries has not yet been addressed.  It must be acknowledged that narrowing of 
the capillary lumen could also be caused by edema of the surrounding tissue and swelling 
of the endothelial cells, both common occurrences in sepsis (21, 28), however edema was 
not observed 24 hours into sepsis when capillary plugging is already present (43).  
Previous studies examining the capillary plugging revealed that during sepsis, many 
capillaries are intermittently perfused (i.e., the red blood cells show stop-and-go 
movement) (2, 57)  This could be explained by the possibility that red blood cells 
encounter a temporary occlusion in the capillary, completely eliminating flow, and then 
re-start the flow following the release of the occlusion.  The observed intermittent flow is 
in direct contrast to what would be expected through closure of a precapillary sphincter, 
where the occluding region would be situated immediately prior to the capillary entrance.   
 The present studies support the notion that during sepsis there is enhanced fibrin 
stabilization due to sepsis-induced increases in PAI-1 expression.  Increased PAI-1 
protein levels may be beneficial to survival from sepsis.  In my pilot experiments, I was 
unable to identify fibrin present solely in capillaries of immunohistological sections of 
the septic skeletal muscle, possibly due to the lack of appropriate antibodies for fibrin.  
As a result, I could not evaluate the potential for stabilization of fibrin by PAI-1 using 
immunohistology. 
 
5.2.3 Ascorbate and capillary plugging 
An intravenous bolus injection of ascorbate has been demonstrated to decrease both 
mortality and capillary plugging in septic mice (49, 57, 58) Chapter 2).  Ascorbate could 
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accomplish this beneficial effect partially through reduced platelet activation and 
aggregation in a P-selectin mediated mechanism (49, 50).  As platelet depletion alone 
cannot account for the reversal of capillary plugging by ascorbate, clearly another 
mechanism is at play.  Ascorbate has been demonstrated to act in an endothelial nitric 
oxide synthase (eNOS) dependent manner (49), suggesting that it may target any proteins 
that are regulated by eNOS-derived NO.  As vascular smooth muscle cell tone is 
regulated by eNOS/NO (10), it is possible that ascorbate-mediated increases in eNOS 
activity may relax the blood vessels.  Though capillaries themselves are not covered with 
smooth muscle cells, it is possible that increased blood flow in the arterioles immediately 
upstream from the plugged capillaries is able to restore perfusion to these capillaries.  
Alternatively, relaxation of venous smooth muscle and subsequent dilation would allow 
blood to properly drain from the capillaries.  Ascorbate has been demonstrated to restore 
the mean arterial pressure in CLP induced septic rats (58).  Ascorbate also inhibits the 
reduced vasoconstriction of arterioles observed in sepsis (35) and restores the arterial 
response to vasoconstrictors in LPS injected humans (44).  These combined arterial 
alterations may improve the capillary perfusion through increased and better regulated 
pressure to drive the blood through individual capillaries.   
 
5.2.4 Fibrinolytic effects of ascorbate 
Fibrinolysis is known to be depressed during sepsis, contributing to the stability of fibrin 
in the vasculature.  A recent study reported that t-PA mRNA is upregulated with 
ascorbate treatment during sepsis (16).  Several other studies have determined that t-PA is 
upregulated upon ascorbate administration in other disease processes (26, 59), though 
others have observed downregulation of t-PA in smokers and diabetics (42, 54).  Studies 
examining the effect of ascorbate on PAI-1 protein are inconclusive, with some evidence 
for downregulation and other studies finding no effect (1, 26, 42, 54).  The present 
studies, in an attempt to clarify the discrepancies in the literature, aimed to examine the 
effect of ascorbate in the context of fibrinolysis.  The evidence obtained in these studies 
suggests that ascorbate may not change the sepsis-altered fibrinolytic system.  In 
Chapters 2 and 3, the data indicate that there is no effect of ascorbate on PAI-1 on a 
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system wide basis.  There may be an effect on the mRNA expression of PAI-1 in skeletal 
muscle, but this finding wasn't consistent with the PAI-1 protein expression.  It is entirely 
possible that ascorbate affects the PAI-1 expression in a delayed manner, however this 
delayed effect could not explain the reperfusion in capillaries seen already 1 hour after 
ascorbate injection.  Data in Figure 2.3 indicate that this delayed effect is unlikely, as at 3 
h post-injection (i.e., 9 h post-FIP), ascorbate had no effect on sepsis-induced PAI-1 
protein increase in the blood plasma.  In Chapter 4, results in vitro suggest that ascorbate 
treatment for 24 hours increases the production of PAI-1 in endothelial cells.  
Interestingly, co-treatment with LPS or TNFα abolished this increase.  It remains unclear 
what the implications of increased PAI-1 would be in a healthy individual, though it 
should be noted that there is no evidence that this increased PAI-1 is released into the 
extracellular space.   
I showed that the platelet PAI-1 protein release is inhibited by ascorbate at low pH.  It is 
worth noting that in a state of acidosis, the combination of reduced platelet PAI-1 release 
and unchanged PAI-1 release by endothelial cells may result in reduced PAI-1 in the 
capillary blood.  The observed reduction in capillary plugging in sepsis seems unlikely to 
be exclusively due to a pH-mediated mechanism given the limited evidence that 
ascorbate reduces blood pH (Chapter 4).  Overall, these findings point to another 
unknown mechanism by which ascorbate acts in a protective manner in the septic 
microvasculature.  
 
5.2.5 Potential non-fibrinolytic effects of ascorbate 
Ascorbate is a well known antioxidant and it is presumable that at least some of its 
beneficial effect is through a reduction of reactive oxygen species.  The fact ascorbate 
acts in a beneficial effect is somewhat paradoxical, as antioxidants would be expected to 
diminish the respiratory burst involved in the immune response (46).  Theoretically, this 
could be counteracted by a bactericidal effect of ascorbate at relatively high doses (20, 
68).  However, in Chapter 3, I have determined that ascorbate did not alter the levels of 
bacteria in any organ aside from the blood.  It is important to note that the animal models 
 
138 
showing a bactericidal effect of ascorbate typically use a chronic dosing of ascorbate. 
This dosing could explain the apparent discrepancy between these studies and the present 
one.  Nevertheless, it has been demonstrated that six hours after ascorbate injection, the 
peritoneal bacterial levels were unaltered (67). 
 Tissue factor, a major initiator of coagulation, has been demonstrated to be 
activated by ROS.  Succinobucol, an antioxidant, reduces this activation (31).  It is 
presumable that the antioxidant action of ascorbate would act in a similar manner, 
reducing tissue factor, and therefore reducing the initiation of coagulation.  As it is 
commonly accepted that abnormal tissue factor expression is a characteristic of sepsis 
(32), reduction of tissue factor would reduce coagulation and arrest the further 
development of microthrombi.  In conjunction with any degree of fibrinolysis (whether 
rescued by ascorbate or not) a reduction in coagulation could lead to a reversal of 
capillary plugging.  Interestingly, depleting tissue factor improves survival during sepsis 
(40), and therefore a reduction in tissue factor may be another mechanism by which 
ascorbate reduces capillary plugging. 
 In addition to changes in the initiation in coagulation, sepsis-induced platelet 
activation (i.e., P-selectin upregulation, aggregation) has been reported to be inhibited by 
ascorbate administration (49, 50).  This reduction in platelet activation would reduce 
microthrombi formation and capillary plugging in sepsis (49).   
To explain the discrepant results of the reported inhibitory effect ascorbate on platelet 
activation (50) and my present study on PAI-1 release, it is possible that ascorbate only 
inhibited some of the thrombin receptors.  Protease activated receptors 1 and 4 (PAR1 
and PAR4) are cleaved by thrombin and activate the cyclic GMP pathway.  It has been 
demonstrated that platelet PAI-1 release is more sensitive to PAR1 (39), while knockout 
of PAR4 almost completely abolished platelet aggregation and significantly increased the 
time required for P-selectin expression (60).  Moreover, the use of a PAR1 antagonist did 
not affect the thrombin stimulated P-selectin release (14).  As PARs have been 
demonstrated to play a role in eNOS derived NO production (23, 64), I speculate that 
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ascorbate is preferentially altering PAR4 rather than PAR1, reducing platelet P-selectin 
expression and platelet activation while maintaining normal PAI-1 release. 
 Another potential non-fibrinolytic effect of ascorbate is to increase red blood cell 
deformability during sepsis (3).  It has been demonstrated that ascorbate is present in red 
blood cells, and that the levels are identical to that of the blood plasma (29).  A reduction 
in blood ascorbate concentration, as observed during sepsis, would presumably lead to a 
reduction in red blood cell ascorbate concentration.  It is unclear how rapidly the red 
blood cells lose their ascorbate content.  However, at 4°C, red blood cells lost nearly 25% 
of their ascorbate content after 6 h of exposure to ascorbate-free medium (29).  It has not 
yet been determined what effect the loss of ascorbate would have on red blood cell 
function.  However, it is likely the loss of this antioxidant would reduce red blood cell 
deformability (and thus promote capillary plugging), because treatment with the 
antioxidant aminoguanidine inhibited this reduced deformability during sepsis (3).   
 
5.2.6 Ascorbate as a treatment in septic patients 
Ascorbate has been demonstrated to be safe even at very high doses.  Human cancer 
patients are routinely given ascorbate at doses approaching, or even exceeding, 1 g/kg 
body weight with minimal side effects (65).  In addition, ascorbate is inexpensive and 
readily available.  Given these characteristics, the only impediment to clinical trials is a 
lack of understanding as to how ascorbate acts in a protective manner.   
 As ascorbate levels are markedly reduced during sepsis (48), supplementation 
with large doses is necessary to restore the blood plasma to normal levels (19, 30, 38).  
There is no evidence of a detrimental effect of ascorbate at high levels in non-cancer 
patients (16, 36, 37), therefore given the demonstrated safety of ascorbate, this is not an 
impediment to its development as a therapy for the treatment of sepsis. 
The use of ascorbate administered with vitamin E reduced mortality and multiple organ 
failure in both septic and non-septic critically ill patients (8, 38).  Very recently, the use 
of ascorbate alone on a small number of severely septic patients (Phase I trial) has been 
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shown to have beneficial effects on various markers inflammation, the length of hospital 
stay, and 28-day mortality (17).   
A randomized controlled study of critically ill patients concluded that administration of 
glutamine and vitamins including ascorbate did not improve the mortality after 28 days 
(22).  It is important to note that this study involved enteral administration of ascorbate 
along with four other vitamins and minerals, rather than a single intravenous bolus of 
ascorbate as it has been used in the present thesis.  It is conceivable that the reduction in 
capillary plugging observed could reduce survival in the longer term (i.e., after 28 days).  
Survival studies in mice show that ascorbate injection at the onset of sepsis, or delayed to 
6 h of sepsis, significantly decreased mortality (57, 67).  I have demonstrated in Chapter 
4 that, after ascorbate administration, the bacterial content in the organs is not altered, 
indicating that ascorbate does not promote the spread of infection, even though increased 
capillary flow could theoretically reduce bacterial trapping in the organs. 
 The efficacy of ascorbate as a treatment may be enhanced due to its high 
bioavailability and ability to accumulate in endothelial cells when given intravenously 
(66).  Ascorbate is rapidly taken up by endothelial cells through vitamin C transporters 
and accumulates to a steady state concentration of approximately 16 mM (66).  Its safety 
and efficacy is further enhanced by the fact that excess circulating ascorbate is rapidly 
excreted from the body by the kidneys (13).  This protects endothelial cells through the 
antioxidant capacity of the ascorbate, while allowing for the normal production of ROS in 
cells involved in the respiratory burst, and preserving the bactericidal role of ROS in the 
immune system (46). 
 Despite the relative safety of ascorbate, high doses can result in discomfort due to 
a number of side effects.  Frequently, patients have gastrointestinal disturbances such as 
nausea, diarrhea and pyrosis and increased urination accompanied by a burning sensation 
(47).  It can also result in red blood cell hemolysis and vitamin B12 deficiency (47).  In 
addition, acidification of the urine over a longer time period (months to years) increases 
the risk of kidney stones (53).  The efficacy of certain drugs can be altered by high dose 
ascorbate, and some pathological conditions, particularly relating to excess transition 
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metal concentration in the blood (including excess iron due to hemocromatosis, 
sideroblastic anemia and thalassemia) can lead to a prooxidant state (47).  These 
conditions are relatively rare, but caution would be necessary when using ascorbate as a 
treatment in these patients. 
 
5.3 Summary, future directions, and overall findings of this 
research  
Overall, the present studies show that sepsis alters the fibrinolytic system, primarily 
through an increase in PAI-1, and that ascorbate does not appear to alter this increase.  In 
Chapter 2, I showed that ascorbate does not alter the sepsis-induced increase in PAI-1 
protein in the skeletal muscle or liver.  Ascorbate did partially restore towards control the 
low platelet count in sepsis.  However, there was no effect on any measurements of the 
coagulability or fibrinolytic potential of the blood.  In Chapter 3, I extended my study to 
confirm that ascorbate did not alter the PAI-1 expression in a variety of different organs, 
confirmed that ascorbate had no effect on the bacterial levels in tissues aside from the 
blood, and determined that there is no effect of ascorbate on neutrophil recruitment to the 
infected organs.  Chapter 4 included an exploration of the effect of ascorbate on PAI-1 
expression and release by platelets and endothelial cells.  I determined that ascorbate may 
inhibit PAI-1 release by platelets at high concentrations, while ascorbate increased 
production of PAI-1 in endothelial cells.  The effect of ascorbate on platelets was 
observed to be pH sensitive; however the implications of this finding are unclear, as it is 
uncertain whether the blood pH would be low enough after ascorbate injection to induce 
this effect.  I demonstrated that PAI-1 mRNA was inhibited by ascorbate in the skeletal 
muscle in Chapter 2.  I have shown that although endothelial cells release PAI-1 protein, 
the overall contribution to the total blood plasma PAI-1 level might be low (Chapter 2).  
Overall, the evidence presented points to a lack of effect of ascorbate on sepsis induced 
PAI-1 expression, suggesting other mechanisms are responsible for the beneficial effects 
of ascorbate seen in the microcirculation. 
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 Several questions remain unanswered about the effect ascorbate might have on 
the fibrinolytic system.  In Chapter 4, I found that low pH inhibits platelet PAI-1 release.  
This finding is intriguing, as unbuffered ascorbate will have some effect on the blood pH, 
particularly near the site of injection.  Future studies should explore this further, 
determining the degree of effect ascorbate has on blood pH, the length of time and 
threshold pH in order to inhibit platelet PAI-1 release, and how long this phenomenon 
lasts after the pH increases.  As severely septic patients have been known to have severe 
acidosis with a blood pH below 6.8 (41), the possibility that low blood pH in conjunction 
with ascorbate might reduce platelet activation and PAI-1 release is intriguing and 
warrants future study.  As a blood pH below 6.8 generally leads to a poor prognosis, it 
should be investigated whether ascorbate can reduce platelet activation in a slightly acidic 
environment between 6.8 and 7.0.  An important question to be answered is whether 
human patients can be effectively administered ascorbate in a buffer at pH 7.2 or whether 
it must be unbuffered to be effective. 
Another question to be explored is the implication of ascorbate increasing PAI-1 protein 
expression in endothelial cells.  It is unclear whether ascorbate is increasing the 
production of PAI-1 or stabilizing the existing PAI-1.  It is also unclear why the PAI-1 
expression would increase after ascorbate treatment, and whether long-term treatment 
with ascorbate would boost PAI-1 protein expression in healthy individuals.  Future 
studies should explore the possibility that PAI-1 protein is increased in healthy humans 
upon ascorbate treatment.  If PAI-1 is indeed increased, it would be necessary to 
determine how this could be beneficial, as this effect would appear to be detrimental at 
first glance.  In addition to the above studies, it is important to continue work with the 
septic model to determine what other pathways ascorbate may affect.  It has yet to be 
determined whether ascorbate affects red blood cell deformability, as this is another 
potential mechanism to explain the protective effect in capillaries.  Importantly, ascorbate 
level in red blood cells reflects that of the blood plasma (29).  To the best of my 
knowledge, it has not been determined whether the sepsis-induced decreases in blood 
plasma ascorbate levels are reflected in the red blood cells. 
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